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CHAPTER I  
 
 
INTRODUCTION 
 
 
Overview 
 
 mTOR is a serine/threonine kinase that integrates a wide array of cellular 
processes, which contribute to mammary gland development and disease. mTOR 
operates downstream and within the PI3K/Akt signaling pathway, functioning in two 
distinct complexes, mTORC1 and mTORC2, whose activity and substrate specificity are 
regulated by complex-specific cofactors. Specifically, mTORC1 requires the cofactor 
Raptor to perform the essential roles of mTORC1 in regulating growth and metabolism. 
Relatively less is known about mTORC2, although its role in cell survival, polarity and 
cytoskeletal dynamics requires its cofactor, Rictor. Importantly, mTORC2 
phosphorylates Akt at Serine-473.  Akt is a critical signaling effector that lies at the apex 
of several potentially oncogenic signaling pathways controlling cell survival, motility, 
proliferation, and metabolism. Akt is activated in response to phosphorylation. 
Interestingly, Akt is phosphorylated at two distinct sites, Serine 473 (by mTORC2) and 
Threonine 308 (in response to PI3K signaling). Once activated by mTORC2, Akt 
signaling activates mTORC1, thus placing mTOR at locations both upstream and 
downstream of Akt in the PI3K/Akt pathway. Abundant evidence demonstrates that 
mTORC2 has numerous substrates unrelated to the PI3K/Akt pathway, although the 
function of mTORC2 in breast cancer is not yet fully understood. 
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 The PI3K/Akt/mTOR is aberrantly activated in 60% of breast cancers, frequently in 
response to HER2 amplification. 20% of all breast tumors bear HER2 gene amplification 
(Figure 1). PI3K/Akt signaling is required for HER2-mediated transformation and 
promotes resistance to HER2 inhibitors, thus defining HER2-amplified breast tumors as 
PI3K-dependent. Since nearly 100% of metastatic HER2-positive breast cancers 
acquire resistance to HER2 inhibitors, a desperate need for new therapeutic targets in 
HER2- amplified breast cancers is evident. Preclinical studies demonstrated that 
everolimus, an mTORC1 inhibitor that can inhibit mTORC2 through indirect 
mechanisms in some cell types, sensitized HER2-amplified tumors to Herceptin. In 
these studies, everolimus inhibited both mTORC1 and mTORC2. Although ATP 
competitive mTORC1/2 inhibitors effectively prevent mTORC2 activity, the negative 
consequences of mTORC1 inhibition [compensatory activation of PI3K signaling, 
immunosuppression] may limit their therapeutic potential.  Thus, while the role of mTOR 
in HER2-amplified breast cancer is evident, a knowledge gap remains regarding the 
specific role and therapeutic potential of mTORC2 in HER2-amplified, PI3K-dependent 
breast cancers. Additionally, because breast tumor cells hijack many signaling 
pathways required for normal tissue processes, understanding the distinct roles of 
mTORC1 and mTORC2 in mammary morphogenesis is necessary. 
 Data from my thesis work is the first to show that Rictor/mTORC2 is required for 
both normal and HER2-transformed mammary epithelial cells (MECs), though, 
interestingly, the Rictor-dependent pathways that regulate normal MEC versus tumor 
cell functions are distinct.  
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Figure 1. Alterations in the HER2-PI3K-Akt pathway in clinical breast tumors.  
HER2-PI3K-mTOR pathway aberrations were assessed in TGCA-curated breast cancers.  
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We found that Rictor/mTORC2 activates Akt to drive survival of HER2-amplified breast 
tumor cells. Interestingly, Akt was not sufficient to restore migration/invasion of Rictor-
deficient HER2-amplified breast cancer cells. Instead, tumor cells downregulate 
RhoGDI2, a Rac1 inhibitor, in order to drive Rictor-mediated Rac1-dependent cell 
migration and metastasis. In contrast, untransformed MECs use an mTORC2-PKCα-
Rac1 signaling pathway that is Akt-independent. Our data uncovers a previously 
unreported role for Rictor/mTORC2 in mammary morphogenesis and HER2-mediated 
tumorigenesis and suggests that mTORC2-specific inhibitors, or Rac inhibitors, may 
improve HER2-positive tumor cell killing in combination with clinically prescribed HER2 
inhibitors.  
The mTOR pathway 
 Mechanistic target of rapamycin (mTOR) is an intracellular serine/threonine 
protein kinase, first discovered as the target of the naturally derived compound, 
rapamycin or sirolimus, which initially gained attention for its wide anti-proliferative 
properties. Studies in yeast identified TOR1 and TOR2, two TOR enzymes encoded by 
distinct genes, as mediators of these rapamycin-induced effects [5]. Observations that 
rapamycin did not inhibit all mTOR functions in mammalian cells ultimately led to the 
discovery that mTOR exists in two structurally and functionally distinct complexes, 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Figure 2) [6]. Each 
mTOR complex is defined by 1) complex-specific co-factors, 2) varying sensitivity to 
rapamycin, 3) distinct signaling inputs, and 4) distinct substrates that regulate diverse 
cellular processes.  
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Figure 2. mTOR exists in two structurally and functionally distinct complexes, 
mTORC1 and mTORC2. Raptor is a required cofactor for mTORC1, while Rictor and 
Sin1 are cofactors required for mTORC2. mTORC1 inhibitors and dual mTORC1/2 
inhibitors exist but mTORC2-specific inhibitors do not currently exist. 
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Both mTOR complexes are large - mTORC1 is comprised of six known subunits and 
mTORC2 is comprised of seven. Each complex shares several components including 
the catalytic mTOR subunit, the mammalian lethal of sec13 (mLST8) protein, and the 
dep-containing mTOR-interacting protein (DEPTOR). In contrast, regulatory associated 
protein of mechanistic target of rapamycin (Raptor) and proline-rich Akt substrate 40 
kDA (Pras40) are mTORC1-specific whereas rapamycin-insensitive companion of 
mTOR (rictor), mammalian stress-activated map kinase-interacting protein (mSin1) and 
protein observed with Rictor 1/2 (Protor 1/2) are mTORC2-specific components (Figure 
3) [reviewed in [7]]. 
 Once rapamycin was identified as an mTORC1 inhibitor, it was quickly 
determined that its mTORC1 inhibitory effects were due to formation of a gain-of-
function complex with the small, intracellular FK506-binding protein (FKBP12) however 
precisely how this complex inhibits mTORC1 is still not fully understood (Figure 4) [8, 
9]. Adding to this complexity, recent studies show that prolonged rapamycin treatment 
can inhibit mTORC2 in a cell type-dependent context, although this mechanism remains 
unclear. For example, prolonged (24 hours) but not acute (1 hour) rapamycin treatment 
in PC3 or HeLa cells decreased Rictor-mTOR interaction and downstream signaling 
[10]. Therefore, while it is clear that rapamycin can inhibit growth of cancer cells in vitro 
and in vivo, the distinct contributions of mTORC1 and mTORC2 in inhibiting these 
processes is still unclear.  
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Figure 3. Schematic representation of mTORC1 and mTORC2. Common cofactors 
include DEPTOR and mLST8. From [3]. 
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mTORC1: activation and main functions 
 mTORC1 is the better characterized mTOR complex. As a main function, 
mTORC1 integrates signals from intracellular and extracellular cues including growth 
factors, stress, oxygen and amino acids to control important cellular processes like 
protein and lipid synthesis, cell growth and autophagy. The signaling pathways directly 
upstream of mTORC1 have been well described and include the tuberous sclerosis 
(TSC) 1/2 complex, a major upstream regulator of mTORC1 that functions as a GTP-
ase activating protein (GAP) for the Ras homolog enriched in brain (Rheb) GTP-ase. 
GTP-loaded Rheb directly interacts with mTORC1 and stimulates its kinase activity, 
while TSC1/2 negatively regulates mTORC1 by converting Rheb into its GDP-bound, 
inactive state.  TSC1/2 directly integrates many of the upstream signals to mTORC1, 
like insulin and insulin-growth factor 1 (IGF1) that stimulate PI3-kinase and Ras 
pathways. PI3K and Ras effectors like protein kinase B (Akt/PKB) and extracellular-
signal-related kinase (Erk) directly phosphorylate TSC1/2 to inactivate it and 
subsequently activate mTORC1. Additionally, the canonical Wnt pathway, a major 
regulator of cell growth, proliferation, polarity, differentiation, and development, inhibits 
glycogen synthase kinase 3 (GSK3-), which normally phosphorylates and promotes 
Akt TSC2 activity, resulting in activation of mTORC1 [11]. 
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Figure 4. Structure of the mTOR complexes. mTOR is a large kinase that 
contains a carboxy-terminal serine/threonine protein kinase domain, 
 
a FAT 
domain and a C-terminal FAT (FATC) domain that is thought to play a role in its 
structure and stability. Mammalian LST8 associates with the kinase domain of 
mTOR and is thought to facilitate mTOR signalling. mTOR and LST8, together 
with RAPTOR form mTORC1. RAPTOR is essential for mTORC1 activity and is 
proposed to interact with mTOR through shared HEAT domains. Rapamycin 
binds to FKBP12 to form a drug–receptor complex that specifically and effectively 
blocks the activity of mTORC1. The rapamycin–FKBP12 complex binds next to 
the kinase region of mTOR in the FKBP12–rapamycin-binding (FRB) domain and 
disrupts the in vitro and in vivo activity of the complex, potentially by disrupting the 
interaction between RAPTOR and mTOR. mTORC2 also contains LST8 but 
specifically associates with RICTOR and MAPKAP1 (also known as SIN1). Unlike 
mTORC1, mTORC2 is resistant to direct inhibition by rapamycin. It is unknown 
what prevents the interaction between the rapamycin–FKBP12 complex and the 
FRB domain on mTORC2.  
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In contrast, hypoxia and DNA damage can inhibit mTORC1 [12]. For example, in 
response to low oxygen levels, adenosine monophosphate-activated protein kinase 
(AMPK) phosphorylates TSC2 and increases its GAP activity towards Rheb to suppress 
mTORC1 function. AMPK can also directly inhibit mTORC1 through phosphorylation of 
Raptor and subsequent allosteric inhibition of mTORC1. DNA damage also signals to 
mTORC1 through multiple p53-dependent mechanisms. Specifically, DNA damage 
induces expression of TSC1 and phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) resulting in downregulation PI3K-mTOR signaling [13]. 
 Notably, amino acids, like leucine and arginine, play an important role in 
mTORC1 activation and their presence is required for activation of mTORC1. Because 
of this, research efforts have been focused on elucidating the specific amino acid 
sensors on mTORC1. Several groups have identified that amino acid-dependent 
activation of mTORC1 requires the Rag GTPases, of which there are four: RagA, B, C 
and D [14]. Rag A or B forms a heterodimer with either Rag C or D each of which have 
opposite nucleotide loading state so that when Rag A/C is in the GTP-bound state, Rag 
B/D is in the GDP-bound state and vice versa. Amino acids promote the loading of GTP 
on Rag A/B, which enables the heterodimer to interact with Raptor, resulting in 
translocation of mTORC1 to the lysosomal surface where the Rag GTPases dock on a 
complex called the Ragulator. Like the Rags, the Ragulator is essential for amino acid 
signaling to mTORC1.  Recent work proposes an inside-out model of amino acid 
sensing in which the accumulation of amino acids in the lysosomal lumen leads to 
initiation of signaling.  
11 
 
These processes are thought to require the vacuolar H+ -adenosine triphosphate 
ATPase (v-ATPase) as depletion of necessary v-ATPase subunits blocks amino-acid-
induced lysosomal localization of mTORC1 and downstream signaling. Additionally, the 
v-ATPase and the Ragulator directly interacted at the lysosomal surface, further 
implicating v-ATPase in integration of amino-acid-stimulated mTORC1 signaling [15]. 
Signaling downstream of mTORC1 
 Control of protein synthesis is a main function of mTORC1 and the effectors 
involved have been well characterized. First, mTORC1 directly phosphorylates 
eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) (Figure 5) 
which results in exclusion from the negative regulator of cap-dependent translation, 
eIF4E. This allows activated 4EBP1 to directly interact as part of the eIF4F complex, 
which is necessary for the initiation of cap-dependent translation. Additionally, direct 
phosphorylation and activation of S6 kinase 1(S6K1) by mTORC1 results in increased 
mRNA production and enhanced translational elongation and initiation. The role of 
mTORC1 in the regulation of mRNA translation has been confirmed using mTORC1-
specific inhibitors in cell culture, showing a significant reduction in overall rates of 
protein synthesis upon treatment with mTORC1 inhibitors. mTORC1 can also control 
the rates of lipid synthesis, a process necessary for the formation of cell membranes. 
These mTORC1-specific functions are, at least partially, through sterol regulatory 
element binding protein 1/2 (SREBP 1/2) transcription factors that control the 
transcription of a number of necessary lipogenic genes, including fatty acid synthase 
(FASN).  
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Figure 5. mTOR is a HER2/PI3K effector and regulates cellular functions in 
development and disease. mTOR exists in two complexes, Raptor-dependent 
mTORC1 and Rictor-dependent mTORC2. Signaling inputs for each complex are shown 
in blue and signaling outputs are shown in gray. mTORC1 and mTORC2 substrates are 
shown in parentheses. 
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mTORC2: assembly and upstream regulators 
  The core components of mTORC2 include mTOR, Rictor, Sin1, protor1/2 and 
mSLT8. The subunit Rictor is a necessary mTORC2 component, since Rictor loss 
decreases mTORC2 stability, activation and downstream signaling [16]. However, it 
should not be overlooked that mTOR-independent roles for Rictor have also been 
described. In one study, Rictor interacted with integrin-linked kinase (ILK) to 
phosphorylate Akt and control survival of breast and prostate cancer cells [17].  
Therefore, it is possible that Rictor possesses additional undiscovered roles, by 
interacting with other kinases independently of mTOR. Similarly, Sin1 [18] and mLST8 
[19] maintain the Rictor-mTOR interaction, which is necessary for mTORC2 signaling, 
as genetic Sin1 or mLST8 ablation in cells or in mice robustly compromises mTORC2 
activity. Additionally, Sin1-null mouse embryonic fibroblasts (MEFs) display impaired Akt 
phosphorylation at Ser473 in response to serum or insulin, while Thr308 
phosphorylation (the PDK1-substrate site) remains intact. Interestingly, loss of 
mTORC2-dependent Akt-S473 phosphorylation blocked Akt-mediated phosphorylation 
of FOXO1/3a, increasing stress-induced cell death despite intact Akt-T308 
phosphorylation and mTORC1 activity [18].  
The upstream factors that activate mTORC2 are not understood fully. Unlike 
mTORC1, mTORC2 is nutrient-insensitive, but does respond to growth factors (e.g., 
insulin), reportedly through PI3K-dependent and ribosome-dependent mechanisms. In 
HeLa cells, ribosomes (but not protein synthesis) are required for proper mTORC2 
assembly and activation.  
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In HeLa cells, insulin-stimulated PI3K signaling increases mTORC2-ribosome 
interaction, while the mTORC2-ribosome interaction promotes Akt Ser473 
phosphorylation in melanoma cells [20].  
Phospho-proteomic studies have revealed at least 21 distinct phosphorylation sites 
on Rictor, uncovering an additional layer of mTORC2 regulation. The vast majority of 
these sites still possess unrevealed functions. However, liquid chromatography mass 
spectrometry (LC-MS) identified Rictor phosphorylation at Thr-1135 as a rapamycin-
sensitive site phosphorylated directly by S6-Kinase (S6K) in response to mTORC1 
signaling. Although a Thr-1135-to-Ala mutant did not affect mTORC2 integrity or in vitro 
kinase activity, a constitutively active Thr-1135 phospho-mimetic mutant increased P-
Akt (S473) beyond what was seen with wild-type Rictor, showcasing another example of 
crosstalk between mTORC1 and mTORC2 [21]. 
Other studies demonstrated that S6K and Akt phosphorylate Sin1 at Thr-86 and 
Thr-398, respectively, resulting in Sin1 dissociation from mTORC2, complex instability, 
impaired Akt phosphorylation and activity, and profoundly decreased tumorigenesis. 
Importantly, the authors identified a cancer-derived Sin1 (MAPKAP1) mutation that 
impairs Sin1 phosphorylation, increasing mTORC2 stability and activity. Together, these 
findings suggest that mTORC1-S6K-Sin1 pathway mutations may increase mTORC2-
Akt, thereby facilitating tumor progression [22]. Clearly, a dynamic interplay between 
Akt, mTORC1 and mTORC2 exists, warranting further efforts to understand the 
consequences of mTORC1 or dual mTORC1/2 inhibitors on feedback signaling through 
the PI3K/Akt/mTOR pathway. 
 
15 
 
mTOR signaling in development 
 As previously mentioned, the mTOR pathway integrates numerous signaling 
pathways to control many processes necessary for cellular function. As such, a vast 
amount of research has been dedicated to elucidating the role of mTOR in physiological 
processes in hopes that these findings could directly apply to pathological states. 
Classic models of gene targeting demonstrated that ablation of mTORC1 or mTORC2 
cofactors leads to embryonic lethality, resulting in limited data generated from these 
studies [18, 19, 23]. However, generation of tissue-specific knockout models in mice 
provided further insight into the relative contributions of mTORC1 versus mTORC2 in 
tissue types. For example, mice with adipose-specific deletion of necessary mTORC1 
cofactors have fewer and smaller adipocytes, resulting in less adipose tissue and 
resistance to obesity induced by high fat diet [24]. In contrast, loss of mTORC2 
signaling in adipose tissue results in decreases activation of Akt S473 and increases 
lipolysis without affecting the number or size of adipocytes [25]. Muscle-specific loss of 
mTORC1 signaling causes decreased muscle mass, oxidative function and ultimately 
leads to early death in mice. In these mice, reduced oxidative metabolism was linked to 
decreased levels of transcriptional regulators of mitochondrial function [26]. Impaired 
mTORC2 signaling in muscle cells produces a different phenotype, with no effect on 
muscle structure but a mild decrease in glucose uptake. These results are interesting 
because while mTORC1’s contribution to glucose metabolism has been well described, 
a role for mTORC2 in these processes is just becoming apparent.  
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 Because the liver plays important roles in the regulation of glucose and 
lipogenesis in response to varying feeding and fasting states, it is not surprising that 
mTORC1 and mTORC2 are essential to hepatic regulation of whole body metabolism. 
Indeed, mTORC1 controls hepatic energy production in response to fasting [27]. 
Additionally, mTORC1 is required for anabolic processes during the fed state through its 
control of the transcription factor SREBP1c [28]. However, the complexity and crosstalk 
between key signaling molecules of the mTOR pathway is apparent as insulin-
stimulated Akt can activate hepatic SREBP1 activity through both mTORC1-dependent 
and mTORC1-independent pathways [29]. Additionally, mTORC2 can also activate 
SREBP1 to control hepatic glycolysis and lipogenesis. In these studies, mTORC2-Akt 
signaling controlled SREBP1, which regulated lipogenesis, and glucokinase (GK) 
activity, which controlled glycolysis [30]. These data provide increasing evidence that 
mTORC2 may control key processes in cell metabolism, which previously have been 
only attributed to mTORC1 signaling.  
 In addition to the cell types already mentioned, essential roles for mTOR 
complexes have also been described in the pancreas where mTORC1-S6K signaling 
and mTORC2-Akt-Foxo signaling controls β-cell mass and function [31, 32]. 
Additionally, brain-specific mTORC1 loss suggests a role for mTORC1 signaling in 
control of energy balance in the hypothalamus [33], while the role for mTORC2 in these 
processes has yet to be clearly defined.  
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While the relative contributions of mTORC1 and mTORC2 have been described for 
many tissues, knowledge gaps remain. For example, the specific roles of mTORC1 and 
mTORC2 in mammary gland development have not yet been explored. This is 
discussed below and is the focus of our studies in Chapter I.  
Mammary gland development  
 The post-natal mammary gland undergoes a complex series of events in which 
an extensively branched ductal network develops from a rudimentary epithelial bud 
(Figure 6) [34].  Pubertal changes trigger the onset of branching morphogenesis which 
is regulated by endocrine hormones and local paracrine interactions with mesenchymal 
stroma [35]. In response to hormonal and growth factor cues, mammary epithelial cells 
(MECs) within the terminal end buds (TEBs) rapidly [34, 35] proliferate and collectively 
invade surrounding stroma.  Differentiation of epithelial progenitors in the TEB 
populates the ducts with mature luminal MECs, and apoptosis canalizes the lumen. 
TEB’s undergo successive rounds of elongation, bifurcation and branching until a 
mature epithelial tree has formed within the virgin gland [34, 35]. The careful 
coordination of numerous molecular signaling pathways is required for the dynamic 
processes that occur during puberty in the mammary epithelium (Figure 7).  
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Figure 6. Schematic representation of the structure of mammary epithelium 
on different stages of differentiation. A. Prepubertal and pubertal mammary 
gland consists of ducts terminated by highly proliferative terminal end buds (TEBs) 
that comprise cap cells in direct contact with basal lamina, and body cells forming 
the bulk of the TEBs. B. During pregnancy, more extensive ductal branching and 
formation of alveolar structures, which are required for milk production, takes place. 
In functionally active mammary glands, alveoli are built by a single layer of milk-
secreting luminal epithelial cells surrounded by myoepithelial cells, and basement 
membrane. Myoepithelial contractions release the milk into the ducts, and further to 
the nipple, whereas basement membrane provides cell contact with the 
extracellular environment. From [4].  
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Figure 7. Mammary gland development during puberty, pregnancy and lactation.   
A. Schematic presentation of the different stages of mammary gland development.  
(a-d) Rudimentary ductal design within the mammary fat pad is visible at birth, which 
grows at the same rate as the animal until the onset of puberty. (a) During puberty, 
cyclical hormone production accelerates ductal outgrowth causing club-shaped 
structures (TEB) where the highest levels of cell division occur to appear at ductal tips. 
(b) In mature virgin, the entire fat pad is filled with a regularly spaced system of primary 
and secondary ducts, with side branches that form and disappear in each oestrous 
cycle. (c) Hormonal changes that occur when pregnancy begins increase cell 
proliferation and the formation of alveolar buds. (d) During lactation, alveoli are fully 
matured and the luminal cells synthesize and secrete milk components in the lumen. 
Following lactation, the mammary gland will undergo massive apoptosis during 
involution to revert back to a mature virgin gland structure. B. Whole mount 
hematoxylin-stained mammary glands corresponding with each stage of development 
and highlighting the major hormone signals involved in each stage. From [2]. 
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PI3K-Akt- mTOR pathway components in mammary gland development 
 The PI3K-Akt-mTOR pathway and its downstream effectors control important 
processes that are necessary for proper mammary gland development. Inasmuch, the 
use of transgenic mouse models has confirmed distinct roles for the Akt isoforms, Akt1, 
2 and 3 in specific stages of mammary gland development. For example, Akt1 is 
required for efficient lactation to support offspring, partially due to inability of Glut1 to 
localize to the plasma membrane and reduced glucose uptake in Akt-deficient mice. 
Additionally, Akt1 knockout mice display reduced lipid synthesis and expression of 
lipogenic enzymes [36].  Conversely, forced expression of a constitutively active Akt1 
results in defects in lactation and delayed involution due to decreased cell death [37, 
38]. Alveolar-specific constitutive Akt activation resulted in aberrant accumulation of lipid 
droplets during pregnancy, and these mice produced small pups, presumably due to 
increased milk fat context/viscosity, which caused decreased suckling in pups [39].  
Interestingly, several studies have revealed opposing roles for Akt1 and Akt2 in 
the developing mammary gland.  Ablation of Akt1 results in delayed development and 
differentiation during pregnancy and lactation whereas Akt2 deficiency results in 
precocious differentiation. Likewise, although involution is accelerated in the absence of 
Akt1, it is delayed in Akt2-deficient mammary glands [40]. Phosphorylated Akt activates 
downstream substrates including the serine/threonine kinase mTOR and the forkhead 
family of transcription factors (FOXO). mTOR uses these substrates to regulate cellular 
metabolism, protein and lipid synthesis, cell survival, and cytoskeletal organization, 
processes that are required for proper mammary morphogenesis.  
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While mTOR regulates MEC growth [41, 42] and milk protein expression in cell lines 
[41, 43-45], mTOR-mediated regulation of mammary ductal morphogenesis remains 
under-investigated, partially due to the lack of specific inhibitors of each mTOR 
complex.  
Dysregulation of PI3K- Akt- mTOR pathway in breast cancer 
 The PI3K-Akt-mTOR pathway is the most frequently altered pathway in breast 
cancer, with alterations occurring in approximately 60% of all breast cancers. These 
alterations often occur in response to HER2 overexpression or activation, which occurs 
in almost 25% of breast cancers. Activating mutations in PIK3CA, the gene encoding 
the p110α catalytic subunit of PI3K, are also common, occurring in 36% of all breast 
cancers, most prevalently in luminal and HER2-amplified tumors. These mutations 
commonly reside in “hot spot” sites, H1047R and E545K, which confer increased PI3K 
catalytic activity resulting in cellular transformation and contribute to resistance to 
HER2-targeted therapies. Additionally, activating mutations in the Akt1 gene are 
observed in approximately 36% of ER+ breast cancers. Amplifications and 
overexpression of AKt1 have also been described, although in a much smaller subset of 
breast cancers. Finally, the tumor suppressor and negative regulator of PI3K signaling, 
PTEN, is mutated or lost in 7% of breast cancers, though almost exclusively in triple 
negative breast cancers (TNBCs). Loss of PTEN protein in tumors results in 
accumulation of PI(3,4,5)P3 and in turn, phosphorylation and activation of Akt.  
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 Several lines of evidence support PI3K pathway alterations as drivers of breast 
cancer formation. For example, active PIK3CA or Akt1 mutants in human MECs results 
in growth factor independence, anchorage independent growth and tumor formation in 
mice.  Importantly, PI3K/Akt pathway re-activation is a major driver of resistance to 
HER2-targeted therapies. For example, PIK3CA mutations can confer resistance to the 
anti-HER2 monoclonal antibody, trastuzumab, which can be overcome by combining 
trastuzumab with PI3K, Akt, or mTOR inhibitors. 
Signaling effectors downstream of mTORC2: important roles in breast cancer 
 mTORC2 directly phosphorylates and activates the AGC kinases including Akt, 
SGK1 and PKC family members [46, 47]. Specifically, the mTOR components Rictor, 
Sin1 and mTOR are each required for carboxy-terminal phosphorylation of both the turn 
motif (TM) and hydrophobic motif (HM) of all conventional protein kinase Cs (PKCs) 
(including PKCα and PKCε), Akt and the HM of serum- and glucocorticoid-induced 
protein kinase 1 (SGK1). 
The serine/threonine protein kinase Akt is a major downstream signaling 
component of the PI3K pathway and upon activation controls cell survival, proliferation, 
migration and glucose metabolism. PI3K signaling recruits Akt to the inner plasma 
membrane, where Akt is phosphorylated at Thr-308 by phosphinositide-dependent 
kinase 1 (PDK1) and at Ser473 by mTORC2. Akt exists in three isoforms: Akt1, 2 and 3. 
Akt 1 and 2 are ubiquitously expressed while Akt 3 expression is expressed in a cell-
type dependent manner. Overexpression studies paired with genetic and 
pharmacological inhibition of Akt have provided insight into Akt’s role in tumor cell 
survival, proliferation and tumorigenesis.  
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Akt’s transforming properties were highlighted in early preclinical studies where 
overexpression of wildtype Akt2 transformed NIH3T3 fibroblasts; NIH3T3 cells 
expressing a constitutively active Akt1 construct (myr-Akt) formed colonies in soft agar, 
produced tumors in mice [48] and rescued apoptosis induced by PTEN [49]. 
Additionally, overexpression of Akt2, but not Akt 1 or 3, increased aggressiveness and 
metastatic properties in human breast cancer cell lines [50]. Transgenic mouse models 
have been beneficial in further dissecting the distinct roles of Akt in tumorigenesis. 
While mice with mammary-specific expression of Akt exhibited delayed postpartum 
involution, tumors did not develop [37], suggesting that an additional oncogenic hit 
might be necessary for overt tumorigenesis 
 Conversely, targeted deletion of Akt in PTEN null embryonic stem cells (ESCs) 
partially reduced tumorigenic properties [51]. Dominant negative forms of Akt block 
insulin-like growth factor 1 (IGF1)-induced cell survival, showcasing Akt’s anti-apoptotic 
roles. Additionally, aberrant Akt activation has been widely described in clinical breast 
cancers, including Akt1 mutations, which occur in breast cancers, albeit at low 
frequencies and Akt1 amplifications, which correlate with poor survival outcome in 
breast cancer patients. More often, Akt is hyperactive due to genetic alterations in 
upstream activators such as HER2 gene amplification and PIK3CA activating mutations 
occur in approximately 25% and 21% of breast cancers, respectively.  
The PKC family of serine/threonine kinases controls several cellular processes, 
including proliferation, migration, and differentiation. PKC members are traditionally 
categorized into three classes termed “conventional”, “novel” and “atypical” [52] and are 
controlled via serine, threonine or tyrosine phosphorylation.  
24 
 
Notably, mTORC2-dependent phosphorylation of the PKC TM regulates maturity and 
stability of all conventional PKC isoforms, including PKCα.   
 PKC gene mutations are relatively rare, but increased PKC expression and/or 
phosphorylation correlate with tumor aggressiveness and decreased survival in breast 
cancer patients. Experimental PKCα over-expression in breast cancer cells increased 
migration, leading to a more aggressive phenotype [53, 54]. Rictor-PKC interactions 
control breast cancer cell migration and metastasis [55].  
 SGK plays important roles in growth factor-induced cell survival. SGK exists in 
three isoforms, SGK1, 2 and 3. Like Akt, SGK1 activation is triggered by two 
phosphorylation events: T-loop phosphorylation on Thr-256 by PDK1 and HM 
phosphorylation at Ser-244 by mTORC2, which is enhanced by stimulation with insulin 
and growth factors [56]. Previous reports have shown that SGK1 activation requires 
PI3K-PDK1 signaling, as PI3K inhibition suppresses SGK1 activity [57]. Elevated SGK1 
expression has been described in clinical breast tumors [58] and in response to Akt 
inhibitors, suggesting overlapping roles for SGK1 and Akt in activating downstream 
effectors and compensation for Akt activity by SGK1 [59]. 
A necessary role for mTORC2 in cancer 
 One of the first described cellular functions of mTORC2 is control of cytoskeleton 
reorganization through regulation of Rho family of GTPases [6]. Additionally, mTORC2 
regulates migration, proliferation and survival in various cell types including neutrophils, 
β-cells, endothelial cells, and primary mammary epithelial cells [31, 60-62]  
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Given the potent roles of cell survival and motility in tumor formation and progression, it 
is not surprising that mTORC2 has recently garnered interest for its potential role in 
cancer. Intriguing studies utilizing mouse models have revealed a necessary role for 
mTORC2 in the formation of PI3K-driven prostate cancer. Although Rictor was 
dispensable for normal prostate development, PI3K-driven prostate tumor formation 
was blocked upon Rictor loss [63]. In gliomas, Rictor overexpression promotes 
mTORC2 activity, tumor cell growth and motility [64], whereas genetic mTORC2 
inhibition (i.e., stable Rictor knockdown) causes cell cycle arrest and decreased colon 
cancer growth [65]. 
Less is known regarding the distinct contributions of mTORC2 to breast cancer 
cells. Preclinical studies using breast cancer models have demonstrated that 
everolimus, an mTORC1 inhibitor that can inhibit mTORC2 through indirect 
mechanisms in some cell types, sensitizes HER2-amplified tumors to the HER2 
inhibitor, trastuzumab. In these studies, everolimus inhibited both mTORC1 and 
mTORC2. Although ATP competitive mTORC1/2 inhibitors effectively prevent mTORC2 
activity, increasing evidence also suggests that targeting mTORC1, via mTORC1-
specific inhibitors, may increase IRS1-to-PI3K signaling and mTORC2-mediated Akt 
phosphorylation, ultimately dampening tumor response and promoting therapeutic 
resistance [66]. Current clinical trials are investigating mTOR kinase inhibitors that block 
both mTORC1 and mTORC2 [67], but little is known about mTORC2 in breast cancer 
formation, progression, and therapeutic response, despite its known role in activation of 
Akt, a key signaling node in many breast cancers. 
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 In vitro experiments have hinted at the importance of mTORC2 in breast cancer 
cells.  Several lines of evidence suggest that cancer cells exploit Rictor-dependent 
mTOR signaling pathways to facilitate invasion and metastasis. For example, siRNA-
mediated Rictor knockdown inhibited MCF7 and MDA-MB-231 breast cancer cell 
migration [55, 68]. Rictor knockdown inhibited transforming growth factor beta (TGFβ)-
mediated epithelial-to-mesenchymal transition (EMT) in breast cancer lines [69]. 
Additionally, Rictor can interact with PKC to regulate breast cancer metastasis [55].   
 Importantly, there is increasing evidence indicating a critical role of Rictor in 
clinical breast tumors. For example, Rictor protein expression is elevated in invasive 
ductal carcinoma compared to normal tissue or ductal carcinoma in situ (DCIS) and this 
correlates positively with lymph node status [55].   
Targeting the PI3K-Akt-mTOR pathway in breast cancer 
As the PI3K-Akt-mTOR pathway is a central signaling pathway that regulates 
many critical aspects of cancer cell physiology, and because it is altered in 60% of 
breast cancers, intense research efforts have focused on developing and testing 
inhibitors of PI3K-Akt-mTOR pathway components for the treatment of breast cancer. 
Abundant evidence from preclinical studies confirms the efficacy of pathway inhibition 
on tumor growth and survival. Additionally, numerous studies confirm a role for the 
PI3K-Akt-mTOR pathway in acquiring resistance to targeted therapies, including HER2-
inhibitors.  
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PI3K pathway inhibition can be achieved in numerous ways including at the level 
of growth factor receptors (through direct inhibition of receptor tyrosine kinases, HER2 
with trastuzumab or EGFR/HER2 with lapatinib), PI3K (through PI3K inhibitors), Akt 
(allosteric and kinase inhibitors of Akt) and mTOR (both mTORC1-specific inhibitors, 
dual mTORC1/2 inhibitors, and dual PI3K/mTOR inhibitors) (Figure 8) [1]. Promising 
results from preclinical data highlighted above has led to clinical trials investigating 
these inhibitors for treatment of breast tumors (Table 1). Given the prominent role of 
mTORC1 in cell cycle progression, intense research efforts have been invested in 
identifying mTORC1 inhibitors. Rapamycin (sirolimus) was the first available mTOR 
inhibitor and is approved for use as an immunosuppressant in transplant recipients. 
Improvements on rapamycin were made and the resulting next generation mTOR 
inhibitors, rapalogues, display better pharmacokinetic and pharmacologic properties. 
Several of these drugs are approved for use in cancers. For example, temsirolimus has 
been approved for the treatment of renal cell carcinoma and everolimus is now 
approved for treatment of patients with renal cell carcinoma, neuroendocrine tumors of 
the pancreas and in postmenopausal women with estrogen receptor (ER) positive 
breast cancer. Additionally, the BOLERO-2 trial, a randomized, phase III trial which 
evaluated everolimus and exemestane in postmenopausal women with hormonal 
positive breast cancer who progressed on aromatase inhibitors, showed that adding 
everolimus to standard chemotherapy significantly improved progression-free survival 
(PFS) in patients [70].  
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Figure 8. Targeting the PI3K-Akt-mTOR pathway in breast cancer.  
Green arrows represent activation of positive regulation, red bars indicate inhibition. Red 
lightning bolts represent genes frequently mutated in human breast cancer. Blue 
rectangles depict drugs either approved or being assessed in clinical trials for breast 
cancer, and the targets they inhibit (black bars). For simplicity, other targets of Akt are not 
shown. P = phosphorylation. RTK = receptor tyrosine kinase. From [1]. 
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Table 1. Drugs Targeting the PI3K-AKT-mTOR Pathway Currently in Clinical Trials for Breast 
Cancer 
Drug Class Study Population(s) Common Toxicities 
Everolimus  
(Rad001) 
Allosteric mTOR inhibitor Adjuvant HR+;locally 
advanced/metastatic, HER2+; 
advanced HER2-negative; 
neoadjuvant 
Fatigue, stomatitis, 
diarrhea, rash 
Temsirolimus Allosteric mTOR inhibitor HER2+ or TN Fatigue, stomatitis, 
diarrhea, rash 
Ridaforolimus  
(MK-8669) 
Allosteric mTOR  
inhibitor 
Advanced/metastatic  
HR+/HER2- 
Fatigue, stomatitis, 
anorexia, diarrhea, 
nausea 
AZD2014 mTOR (TORC1/2)  
kinase inhibitor 
Advanced/metastatic HR+ Fatigue, 
stomatitis, 
anorexia, 
diarrhea, nausea 
MK-2206 Allosteric Akt inhibitor HR+ neoadjuvant and advanced; 
preoperative biomarkers, all  
subtypes; advanced HER2+ 
Rash, nausea,  
pruritus,  
hyperglycemia, 
diarrhea 
AZD5363 Akt kinase inhibitor Advanced/metastatic, all subtypes Not reported 
Triciribine Akt inhibitor Neoadjuvant; advanced  
HER2- 
Hyperlipidemia, 
hyperglycemia,  
fatigue 
GDC-0941 PI3-kinase inhibitor Advanced/metastatic HR+,  
HER2+, TN 
Fatigue, nausea, 
diarrhea, rash, 
transient 
hyperglycemia 
BKM120 PI3-kinase inhibitor Advanced/metastatic HR+ or TN; 
neoadjuvant HER2+; preoperative 
biomarker; advanced HER2+  
resistant to trastuzumab 
Fatigue, rash, 
nausea, mood 
alteration, 
hyperglycemia 
BAY80-6946 PI3-kinase inhibitor Advanced/metastatic Not reported 
XL147 PI3-kinase inhibitor Advanced/metastatic HR+; 
advanced/metastatic HER2+ 
progressing on trastuzumab  
Rash, hyperglycemia 
BYL719 PI3-kinase/PIK3CA-
specific inhibitor 
Advanced/metastatic HR+ Hyperglycemia, 
nausea, vomiting, 
diarrhea, anorexia 
XL765 Dual PI3-kinase/mTOR 
inhibitor 
Advanced/metastatic HR+ Nausea, diarrhea, 
anorexia, rash,  
elevated LFTs 
BEZ235 Dual PI3-kinase/mTOR 
inhibitor 
HER2+;preoperative biomarker; 
advanced/metastatic  
HER2- 
Nausea, vomiting, 
diarrhea, fatigue, 
anemia 
GDC-0980 Dual PI3-kinase/mTOR 
inhibitor 
Advanced/metastatic HR+ Nausea, fatigue,  
diarrhea 
 
 
 
 
 
 
Table 1. Drugs targeting the PI3K-AKT-mTOR pathway currently in clinical trials for 
breast cancer. Adapted from [1]. 
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Additional clinical trials have also demonstrated a significant improvement in 
patients with neoadjuvent everolimus plus letrozole [71] or the addition of everolimus to 
tamoxifen [72], suggesting that mTOR inhibition may play a significant role in hormonal-
positive breast cancers. Unfortunately, the progression-free survival for these studies 
was still only 6 months, suggesting that patients developed resistance to the 
combination of endocrine therapy plus mTOR inhibition. More studies will be needed to 
identify which patients are most likely to benefit and what additional mechanisms of 
resistance may contribute to response. 
As numerous preclinical studies have implicated the PI3K-Akt-mTOR pathway in 
resistance to treatment with the HER2-monoclonal antibody, trastuzumab, clinical trials 
adding everolimus to trastuzumab and cytotoxic therapy in patients with metastatic 
HER2-positive breast cancer are underway. In one trial, the addition of everolimus 
significantly improved progression-free survival, albeit by only a few months [73]. This 
study and others support the idea that mTOR inhibition may improve the response of 
patients with HER2-overexpressing tumors that are resistant to trastuzumab. More 
recently developed ATP-competitive mTOR kinase inhibitors that are designed to 
simultaneously block both mTORC1 and mTORC2 and are also being tested in clinical 
trials. INK128, an orally bioavailable and selective inhibitor of both mTORC1 and 
mTORC2, is being evaluated in phase I clinical trial of patients with advanced solid 
tumors. This trial is ongoing, but INK128 was well-tolerated at the doses and schedules 
tested and preliminary data showed anti-tumor data in some cancer types [74].  
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While multiple PI3K and Akt inhibitors are currently being tested in clinical trials, 
none are currently approved for treatment of breast cancer. These inhibitors have 
exhibited high dose-limiting toxicities, with adverse events including nausea, diarrhea, 
vomiting and fatigue. BKM120, an oral, selective pan class I PI3K inhibitor, has been 
used in phase I dose escalation studies for patients with advanced solid tumors. It was 
safe and well-tolerated in these studies and is now being tested in combination with 
chemotherapy and endocrine therapy to determine if this combination will overcome 
resistance to hormonal therapy. Selective p110α inhibitors are being evaluated in phase 
I studies of metastatic solid tumors and dual PI3K/mTOR inhibitors like BEZ235 are 
being tested in phase I studies in the setting of metastatic breast cancer. These trials 
are ongoing (Reviewed in [75]).  
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Chapter II 
 
MTOR DIRECTS BREAST MORPHOGENESIS THROUGH A RICTOR-DEPENDENT 
PKCα-RAC1 SIGNALING AXIS THAT IS AKT-INDEPENDENT  
 
 
The work presented in this chapter is published in PLOS Genetics under the same title 
 
Abstract 
Akt phosphorylation is a major driver of cell survival, motility, and proliferation in 
development and disease, causing increased interest in upstream regulators of Akt like 
mTOR complex 2 (mTORC2). We used genetic disruption of Rictor to impair mTORC2 
activity in mouse mammary epithelia, which decreased Akt phosphorylation, ductal 
length, secondary branching, cell motility, and cell survival. These effects were 
recapitulated with a pharmacological dual inhibitor of mTORC1/mTORC2, but not upon 
genetic disruption of mTORC1 function via Raptor deletion. Surprisingly, Akt re-
activation was not sufficient to rescue cell survival or invasion, and modestly increased 
branching of mTORC2-impaired mammary epithelial cells (MECs) in culture and in vivo. 
However, another mTORC2 substrate, protein kinase C (PKC)-α, fully rescued 
mTORC2-impaired MEC branching, invasion, and survival, as well as branching 
morphogenesis in vivo.  PKCα-mediated signaling through the small GTPase Rac1 was 
necessary for mTORC2-dependent mammary epithelial development during puberty, 
revealing a novel role for Rictor/mTORC2 in MEC survival and motility during branching 
morphogenesis through a PKCα/Rac1-dependent mechanism.  
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Introduction 
Post-natal mammary epithelial morphogenesis is a complex process during which 
an extensively branched ductal network develops from a rudimentary epithelial bud [34].  
Branching morphogenesis is most active during puberty and is regulated by endocrine 
hormones and local paracrine interactions with mesenchymal stroma [35]. In response 
to hormonal and growth factor cues, mammary epithelial cells (MECs) within the 
terminal end buds (TEBs), the club-shapes structures at the distal epithelial tips [34, 35], 
proliferate and collectively invade surrounding stroma.  Differentiation of epithelial 
progenitors in the TEB populates the ducts with mature luminal MECs, and apoptosis 
canalizes the lumen. TEB bifurcation results from mechanical restraints at the TEB 
midline, forming new primary ducts. Side-branches sprout laterally from the trailing 
ducts as proliferative out-pouchings. Primary and side branching reiterates, filling the 
entire mammary fat pad [34, 35]. Many molecular signaling pathways carefully 
coordinate the dynamic processes that occur during puberty in the mammary 
epithelium.    
The intracellular serine/threonine kinase mammalian target of rapamycin (mTOR) 
regulates cellular metabolism, protein and lipid synthesis, cell survival, and cytoskeletal 
organization, processes that are required for proper mammary morphogenesis.  mTOR 
regulates these processes through phosphorylation of its target substrates, including 
translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1),  p70S6 kinase (S6K), 
Akt, SGK1, and protein kinase C-α(PKCα) [76].  
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mTOR functions in two distinct complexes, each defined by the specific co-factors 
in complex with mTOR kinase and by their relative sensitivity to rapamycin. The 
rapamycin-sensitive mTOR complex (mTORC)-1 requires the co-factor regulatory-
associated protein of mammalian target of rapamycin (Raptor), whereas mTORC2 
requires the co-factor rapamycin-insensitive companion of mammalian target of 
rapamycin (Rictor). Although mTORC2 is relatively insensitive to acute rapamycin 
treatment, more recent studies determined that prolonged rapamycin treatment can 
inhibit mTORC2 complex assembly [10, 77-79]. The intracellular serine/threonine kinase 
Akt is phosphorylated at S473 directly by mTORC2 and is key effector for many of the 
biological effects initiated by mTORC2. Akt is also linked to activation of mTORC1 
downstream of PI3-kinase, making Akt a point of intersection between mTORC1, 
mTORC2, and their associated effectors [76]. 
Though mTOR regulates MEC growth in cell lines [41, 42] and milk protein 
expression [41, 43-45], mTOR-mediated regulation of mammary ductal morphogenesis 
remains under-investigated. The signaling complexity of mTOR, its pleiotropic functions, 
and a lack of mTORC2-specific inhibitors present a challenge to dissecting the relative 
roles of mTORC1 and mTORC2 in mammary development. Given the importance of 
mTOR in breast cancer progression and treatment, an understanding of mTORC1 and 
mTORC2 in untransformed MECs is needed. We assessed the impact of tissue-specific 
Rictor and Raptor ablation on mammary morphogenesis. Rictor loss impaired mTORC2 
activity, reduced ductal lengthening and secondary branching, and reduced MEC 
proliferation and survival in vivo and ex vivo.  
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Surprisingly, genetic disruption of mTORC1 via Raptor ablation resulted in distinct and 
milder effects on the developing mammary ductal epithelium, revealing non-overlapping 
roles for mTORC1 and mTORC2 during mammary morphogenesis. Interestingly, we 
found that mTORC2 controls mammary morphogenesis through downstream effectors 
PKCα and Rac1, but not Akt.  
Materials and Methods 
Mice. All animals were housed under pathogen-free conditions, and experiments were 
performed in accordance with AAALAC guidelines and with Vanderbilt University 
Institutional Animal Care and Use Committee approval. RictorFL/FL mice (C57BL/6) were 
kindly provided by Dr. Mark Magnuson (Vanderbilt University) and have been previously 
described [23]. RaptorFL/FL mice [[19], C57BL/6] were purchased from the Jackson 
Laboratories (Bar Harbor, ME). MMTV-Cre mice[[80] FVB] were purchased from the 
Jackson Laboratories.  All analyses were performed on age-matched siblings resulting 
from F1 (1:1, FVB:C57BL/6) intercrosses. 
PMEC and Organoid Cell Culture. Primary mammary organoids were generated from 
freshly collected, partially disaggregated mouse mammary glands using a modification 
of previously described methods [81]. Primary mouse mammary epithelial cells 
(PMECs) were harvested as described previously [82]. Organoids were immediately 
embedded in growth factor reduced Matrigel (BD Bioscience) at 50 organoids/100 µl. 
Once polymerized, Matrigel-embedded cultures were overlain with Growth Media 
[DMEM:F12 supplemented with 5 µg/ml porcine insulin (Sigma-Aldrich), 10 pg/ml each 
estrogen and progesterone (Sigma-Aldrich), 5 ng/ml human epidermal growth factor 
(R&D Systems), 100 I.U./ml penicillin-streptomycin (Life Technologies)].  
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PMECs were maintained in Growth Media. For some experiments, cells were 
maintained for 24 hour in Starvation Media [Growth Media supplemented with penicillin-
streptomycin only] or treated with Fibroblast-Conditioned Media (DMEM:F12  
supplemented 100 I.U./ml penicillin-streptomycin cultured with mouse mammary 
fibroblasts for 48 hours and passed through a 0.2 µm filter) for wound closure migration 
studies. Rapamycin (Sigma-Aldrich, 20 nM), In Solution Rac1 inhibitor 
(Calbiochem/Millipore, 20 µM), and adenoviral particles (Ad.Cre, Ad.LacZ, Ad.caRac1, 
Ad.Aktmyr, and Ad.PKCα, Vector Biolabs) were purchased. Freshly collected organoids 
were incubated with adenoviral particles (5 X 108 particle forming units/ml) with constant 
rocking for 3-5 hours at 37C, washed, and embedded in Matrigel.  
Morphogenesis in organoids was scored by counting the number of branches/organoid 
in 10 or more organoids/culture condition. For structures that appeared more spherical 
and less branched (e.g. cultures treated with Ad.Cre or inhibitors), we counted 
bifurcations and/or small protrusions from ball-shaped structures as branches in order to 
be as rigorous and conservative in our quantifications as possible. Organoid size was 
scored using NIH Image J software to quantify pixel area in 10 or more 
organoids/culture condition. 
MCF10A Cell Culture. MCF10A and MCF10A RictorZFN were purchased from Sigma-
Aldrich and cultured in Growth Medium [DMEM:F12 supplemented with 5% Horse 
Serum (Life Technologies), 10 µg/ml porcine insulin (Sigma-Aldrich), 20 ng/ml human 
epidermal growth factor (R&D Systems), 10 ng/ml cholera toxin (Sigma-Aldrich), 100 
ng/ml hydrocortisone (Sigma-Aldrich), 100 I.U./ml penicillin-streptomycin (Life 
Technologies)].  
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For some experiments, cells were maintained for 24 hour in Starvation Media [Growth 
Media without serum or EGF] prior to stimulation and/or analysis. PKCα inhibitor 
GO6976 (Sigma-Aldrich, 2 nm) and adenoviral particles (Ad.RFP and Ad.PKCα, Vector 
Biolabs) were purchased. Cells were incubated with adenoviral particles (5 X 108 
particle forming units/ml) for 3-5 hours at 37C and cells were allowed to recover for 48 
hours prior to experimental analysis.  
Immunofluorescence. Matrigel-emdedded organoids cultured on coverslips were fixed 
8 minutes in 1:1 methanol:acetone at -20ºC, permeabilized in 0.5% Triton-X 100/PBS 
for 10 min, blocked [130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 
0.1% bovine serum albumin, 0.2% Triton-X 100, 0.05% Tween-20] and stained with 
rabbit anti-pan-cytokeratin (Santa Cruz Biotechnology, 1:100) and AF621-goat anti-
rabbit (1:100), counterstained with TO-PRO-3 Iodide (Invitrogen), and imaged using the 
Vanderbilt Cell Imaging Shared Resource Zeiss LSM 510 confocal microscope and 
LSM Image Browser software.  
Western blotting. Cells and tissues were homogenized in ice-cold lysis buffer [50 mM 
Tris pH 7.4, 100 mM NaF, 120 mM NaCl, 0.5% NP-40, 100 µM Na3VO4, 1X protease 
inhibitor cocktail (Roche)], sonicated 10 s, and cleared by centrifugation at 4ºC, 13,000 
x g for 5 min. Protein concentration was determined using BCA (Pierce).  
Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, 
blocked in 3% gelatin in TBS-T [Tris-buffered saline, 0.1% Tween-20), incubated in 
primary antibody overnight and in HRP-conjugated anti-rabbit or anti-mouse for 1 h, and 
developed using ECL substrate (Pierce).  
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Antibodies used: α-actin (Sigma-Aldrich; 1:10,000); AKT and S473 P-Akt (Cell 
Signaling; 1:2,000 and 1:500, respectively); S6 and P-S6 (Cell Signaling; 1:1,000); 
Rictor (Santa Cruz; 1:250); Raptor (Cell Signaling; 1:500); Rab11 (Cell Signaling; 
1:1,000); PKCα and T638/641 P-PKCα (Cell Signaling; 1:2,000); Rac (BD Transduction; 
1:200). GST-Pak-PBD effector pulldown assays were performed using reagents from 
Millipore as per manufacturer’s protocol. 
Histological analysis. Mammary glands were whole-mounted on slides, cleared of 
adipose, and stained with hematoxylin as described previously [82]. Sections (5-m) 
were stained with hematoxylin and eosin. In situ TUNEL analysis was performed on 
paraffin-embedded sections using the ApopTag kit (Calbiochem). IHC on paraffin-
embedded sections was performed as described previously [83] using: Ki67 (Santa 
Cruz Biotechnologies), P-S6 (Cell Signaling Technologies); P-Akt S473 (Cell Signaling 
Technologies); Rictor (Santa Cruz), E-cadherin (Transduction Labs). Immunodetection 
was performed using the Vectastain kit (Vector Laboratories), AF488-conjugated anti-
rabbit, or AF621-conjugated anti-mouse (Life Technologies), according to the 
manufacturer’s directions.  
In situ Rac-GTP assay. Methanol-fixed PMECs were probed 1 hour with GST-PBD 
(Millipore) diluted 1:50 in PBS. GST (lacking PBD) was used as a negative control. 
Samples were washed then probed with AF488-conjugated anti-GST (1:100), stained 
with DAPI or AF621-phalloidin, and mounted.  
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Transwell migration and wound closure assays. MECs (105) were added to upper 
chambers of Matrigel-coated transwells in starvation medium and incubated 5 h. Filters 
were swabbed and stained with 0.1 % crystal violet [84] and cells on the lower surface 
were counted. For wound closure, 50,000 MECs were plated on Matrigel-coated 24 well 
plates, grown to confluence, serum-starved for 24 hours, and wounded with a P200 
pipette tip. Migration was scored by measuring the [width of the wound area at 24 
hours] ÷ [width of the wound area at 0 hours]  as described previously [85].  
Microscope Image Acquisition. Mammary gland whole-mounts and transwell filters 
were imaged with Olympus SZX12 Inverted Microscope. Slides were imaged with 
Olympus BX60 Stereo Microscope. Organoids, annexin V-FITC-staining, and wound 
closure assays were imaged with Olympus IX71 Inverted Microscope. All images were 
acquired by Olympus DP 72 Digital Camera and CellSens software at ambient 
temperature.  
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Results 
Rictor/mTORC2 regulates ductal branching, lengthening, and cell survival in the 
mammary gland in vivo 
To assess the role of Rictor/mTORC2 during mammary morphogenesis in the 
context of the native mammary microenvironment, we bred MMTV-Cre mice [80] to 
RictorFL/FL mice [23], allowing mammary-specific Cre recombinase to disrupt Rictor 
expression at floxed (FL) Rictor alleles. Immunohistochemistry (IHC) for Rictor revealed 
expression in luminal and myoepithelial MECs in Rictor+/+MMTV-Cre (RictorWT) mice 
(Figure 9A – upper panel). Rictor expression was not seen in RictorFL/FLMMTV-Cre 
(RictorMGKO) luminal MECs, and was slightly reduced in the myoepithelium, consistent 
with luminal but not myoepithelial Cre expression in MMTV-Cre mice. Akt 
phosphorylation at S473, the mTORC2 phosphorylation site, was decreased in MECs of 
RictorMGKO mice versus RictorWT, confirming decreased mTORC2 signaling upon Rictor 
ablation (Figure 9A – lower panel). Immunofluorescent (IF) staining for cytokeratin 
(CK)-8 and CK14, molecular markers of luminal and myoepithelial MECs, respectively, 
confirmed that Rictor loss did not affect the relative spatial organization of luminal and 
myoepithelial MECs (Figure 9B – upper panel), but revealed the presence of apically 
mis-localized nuclei in RictorMGKO MECs (yellow arrows), versus basally located nuclei 
and an organized, smooth apical border in RictorWT samples (white arrows). 
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Figure 9. Loss of Rictor disrupts mammary branching morphogenesis in vivo.  
A. IHC for Rictor (upper panels) and P-Akt S473 (lower panels) in mammary gland 
sections from virgin mice. B. IF for CK8, CK14, ZO-1 and P120 in mammary gland 
sections. Yellow arrows indicate apically mis-localized nuclei in RictorMGKO tissue in 
upper right panel. White arrows indicate adherens junctions (AJ) in lower left panel. 
C. Hematoxylin and eosin (H&E)-stained mammary sections. Black arrows indicate 
irregular apical border in middle right panel. Black arrow indicates body cells 
sloughing in the TEM lumen and (*) indicates stromal thickening at the neck 
between the maturing duct and TEB. D. Whole mount H&E-stained mammary 
glands from 6-week virgin mice; lymph nodes (LN); terminal end buds (TEB’s, 
arrows). E. Average ductal length (μm) beyond the mammary lymph node (left) and 
average number of side branches (right), ± S.D. F. IHC for Ki67 (upper panels) and 
TUNEL (lower panels) in mammary glands from 6-week old mice. Representative 
images are shown. G. Average percent Ki67+ nuclei (left) or TUNEL+ nuclei (right) 
per total MEC nuclei, ± S.D. N=10 mice for each genotype/time point. Student’s T-
test.  
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IF for the tight junction (TJ) protein Zona Occludens-1 (ZO-1) revealed apical ZO-1 
localization in RictorWT samples.  However, ZO-1 was aberrantly localized along baso-
lateral membranes in RictorMGKO MECs (Figure 9B – lower panel). In contrast, the 
baso-lateral localization of the adherens junction (AJ) protein p120 was relatively 
unaltered by Rictor loss. These results suggest that Rictor loss disrupts the proper 
apical distribution of ZO-1 in MECs. The apically mis-localized nuclei apparent in 
histological mammary sections from 6-week old RictorMGKO female mice contributed to 
an irregular apical border (Figure 9C, black arrows). Additional structural alterations 
were seen in TEBs, including sloughing of body cells (the multi-layered TEB 
population comprised of mature and progenitor luminal MECs; Figure 9C – lower 
panel, arrow) within TEB lumens, and stromal thickening at the neck between 
maturing ducts and TEBs (Figure 9C – lower panel, *). Morphological alterations 
were seen throughout whole mounted, hematoxylin-stained RictorMGKO mammary 
glands (Figure 9D, arrows, Figure 10A). Because mammary ducts lengthen distally 
at a predictable rate during puberty, we measured ductal length in mammary glands 
from 6 week- (mid-puberty) and 10 week-old (late puberty) mice. Ductal length was 
significantly reduced in RictorMGKO mammary glands at both time points (Figure 9E – 
left panel, Figure 10B). Primary (Y-shaped) and side (T-shaped) branches were 
counted in each mammary gland, revealing a significant reduction in T-shaped side 
branches at 6 and 10 weeks of age in RictorFL/FLMMTV-Cre samples as compared to 
RictorWT (Figure 9E – right panel).  
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Figure 10. Loss of Rictor decreases proliferation and survival of MECs in vivo. 
A. RictorWT mice and RictorMGKO mice. High magnification panels show irregular 
ductal tracts and increased staining density in RictorMGKO samples, indicative of 
multiple cell layers. Data are a representation of 11 independent animals/genotype. 
B. Hematoxylin stained whole mount preparations from 10-week-old wild-type 
RictorWT mice and RictorMGKO mice show sustained length defects in the ductal tracts 
of mammary glands lacking Rictor. C. IHC for Ki67 or TUNEL in TEBs from 6-week-
old wild-type RictorWT mice and RictorMGKO mice. Average percent Ki67 and TUNEL+ 
nuclei (± S.D.) was determined. D. Confocal analysis of primary organoids (PMOs) 
stained for E-cadherin (red) revealed multiple cell layers in acinar structures and 
poor lumen formation in Rictor-deficient (RictorFL/FL organoids infected with Ad.Cre) 
PMOs relative to control PMOs (RictorFL/FL organoids infected with Ad.LacZ), 
consistent with the phenotype in RictorMGKO epithelium in vivo. 
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IHC analysis of Ki67 in both ducts and TEBs was used as a relative measure of cellular 
proliferation in the mammary epithelium (Figure 9F - upper panel, Figure 10C – upper 
panel), revealing decreased Ki67+ nuclei in RictorMGKO samples as compared to 
RictorWT at 6 weeks of age but not at 10 weeks (Figure 9G - left panel). Cell death in 
ductal MECs or TEBs, measured using TUNEL analysis (Figure 9F - lower panel, 
Figure 10C – lower panel), demonstrated a remarkable increase in TUNEL+ MECs in 
RictorMGKO samples at 6 and 10 weeks of age (Figure 9G - right panel). These results 
demonstrate that Rictor loss impairs mTORC2 activity, P-Akt, MEC growth, and MEC 
survival during mammary morphogenesis. 
Defects in MEC survival, branching, and motility are recapitulated by Rictor loss 
in an ex vivo model of mammary morphogenesis. 
 Western analysis of whole mammary lysates harvested from 10-week old female 
mice confirmed decreased P-Akt S473 in RictorMGKO mammary glands, and revealed 
increased phosphorylation of the mTORC1 effector ribosomal protein S6 [86] (Figure 
11A) confirming that Rictor loss decreases mTORC2 activity, but not mTORC1.   To 
dissect more precisely how Rictor signaling affects mammary morphogenesis, we used 
primary mammary epithelial cells (PMECs) and primary mammary organoids (PMO’s) 
harvested from RictorFL/FL mice. Adenoviral infection of RictorFL/FL PMECs with Ad.Cre 
significantly reduced Rictor and P-Akt S473 levels relative to cells infected with control 
Ad.LacZ, and increased P-S6 levels (Figure 11B), similar to the impact of Rictor 
ablation in vivo.  
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Figure 11. Impaired survival and morphogenesis of mammary epithelial 
structures upon loss of Rictor ex vivo. A. Western analysis of whole mammary 
lysates harvested from 10-week old female mice. B-C. RictorFL/FL PMECs were infected 
with Ad.Cre or Ad.LacZ and cultured 7 days. B. Western analysis of PMEC lysates 
under serum starved conditions. Quantitation was performed using Image J software 
and numbers represent P-Akt or P-S6 bands normalized to total Akt or S6 levels. C. 
BrdU+ (left) and TUNEL+ (right) nuclei relative to total nuclei were quantified. N = 5 
epithelial isolates, each analyzed in triplicate. Midline values indicate average, whiskers 
indicate S.D., Student’s T-test. D-E. MCF10A and MCF10A-RictorZFN cells were 
analyzed. D. Western analysis of MCF10A lysates. E. Cells were labeled with Annexin 
V-FITC for 6 hours then photographed. Percent Annexin V+ cells versus total was 
quantified, average ± S.D. shown. N = 3 independent experiments, each analyzed in 
quadruplicate, representative images shown, Student’s T-test.  F-I. RictorFL/FL PMECs 
and organoids were infected with Ad.Cre or Ad.LacZ. F. Organoids photographed after 
10 days in Matrigel culture. Representative images are shown.  G. Average organoid 
size, measured in pixel area using Image J software,  ± S.D. (left panel) and average 
number of branches/organoid ± S.D. (right panel) are shown. N = 6 independent 
organoid isolates, analyzed in triplicate, Student’s T-test. H. Western analysis of PMEC 
lysates. I.  Transwell invasion of adenovirus-infected RictorFL/FL PMECs in response to 
serum at 24 hours. N = 6 PMEC isolates/condition, one-way ANOVA.  J.  Transwell 
invasion of MCF10A and MCF10A-RictorZFN cells in response to serum at 24 hours is 
shown as average number of invading cells ± S.D.  N = 3, independent experiments, 
each analyzed in triplicate, Student’s T-test. 
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Consistent with structural alterations were seen in our RictorMGKO model in vivo (e.g. 
sloughing of body cells in TEBs, irregular ductal tracts, multiple cell layers), confocal 
analysis of Rictor-deficient stained for E-cadherin revealed multiple cell layers in 
acinar structures and poor lumen formation relative to control PMOs infected with 
Ad.LacZ, which formed a well-defined lumen surrounded by a single layer of epithelial 
cells (Figure 10D). Rictor loss did not significantly impact PMEC proliferation, as 
measured by bromodeoxyuridine (BrdU) incorporation into genomic DNA (Figure 11C 
– left panel). However, the percentage of TUNEL+ PMEC nuclei was increased >2-
fold following Ad.Cre infection (Figure 11C – right panel), consistent with increased 
cell death in Rictor-null MECs in vivo. Similar results were seen using MCF10A 
immortalized human MECs, in which Rictor gene targeting with Rictor-specific zinc 
finger nucleases (ZFNs) genetically impaired Rictor expression and decreased P-Akt 
S473 (Figure 11D), thus validating our findings in a human MEC model. Increased 
cell death was also seen in MCF10A-RictorZFN cells as compared to parental MCF10A 
cells, as shown by Annexin V-FITC binding (Figure 11E). Therefore, Rictor is 
necessary for mTORC2 signaling and cell survival in human and mouse MECs.  
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  Figure 12. Loss of Rictor impairs branching and lumen formation in organoid 
culture. Primary organoids (PMOs) were isolated from RictorFL/FL mice and infected 
with Ad.GFP or Ad.Cre. A. Fluorescent imaging of organoids 24 hours post-infection. 
B. Confocal analysis of WT organoids infected with Ad.GFP. C. Organoids were fixed 
10 days post-infection and subjected to immunofluorescent staining using a pan-
cytokeratin antibody (red) to confirm epithelial identity and ToPro-3 nuclear marker 
(blue). While Ad.LacZ-infected RictorFL/FL organoids formed hollow lumens 
surrounded by an organized epithelial layer, Ad.Cre-infected RictorFL/FL organoids 
remained rounded and disorganized. Data are a representation of 3 independent 
organoid isolates. D. MCF10A parental or MCF10A-RictorZFN cells were assessed for 
invasion through Matrigel-coated transwell filters. The cells remaining in the upper 
chamber after 24 hours were fixed and stained with either DAPI (blue) or Annexin V-
FITC (green). The average percent viable cells (± S.D.) left in the upper chamber was 
quantitated using Image J, Student’s T-test. 
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We cultured RictorFL/FL mammary organoids in three-dimensional (3D) Matrigel to 
assess collective epithelial morphogenesis (Figure 11F). Mammary organoids 
accurately model epithelial autonomous molecular events of mammary 
morphogenesis in a stroma-free environment that preserves the native relationship 
between luminal and myoepithelial MECs, and permits cell-cell and cell-matrix 
interactions in three dimensions [81]. GFP fluorescence in organoids infected with 
Ad.GFP or Ad.Cre-IRES-GFP confirmed efficient infection in basal and luminal cells of 
organoids (Figure 12A, B). IF staining for pan-cytokeratin confirmed that organoids 
were epithelial-derived (Figure 12C).  Ad.Cre infection of RictorFL/FL PMECs 
substantially reduced organoid size and branching (Figure 11F, G) and reduced 
Rictor expression levels (Figure 11H). In contrast, Ad.Cre infection of RictorFL/+ 
PMECs only modestly reduced Rictor expression levels (Figure 11H) and did not 
significantly affect organoid size or the number of branches formed in RictorFL/+ 
organoids (Figure 11F, G). These data suggest that Rictor is necessary for 
multicellular morphogenesis of the mammary epithelium, faithfully recapitulating ex 
vivo the consequences of Rictor ablation that are seen in vivo and demonstrating the 
utility of this model to examine branching mammary gland morphogenesis. 
Previous studies demonstrated that Rictor knock-down reduces migration of 
breast cancer cell lines [17, 55, 87]. We assessed PMEC invasion and motility through 
Matrigel-coated transwell filters upon Rictor ablation ex vivo. Fewer RictorFL/FL PMECs 
invaded through Matrigel when infected with Ad.Cre, as compared to RictorFL/FL 
PMECs infected with control Ad.LacZ (Figure 11I).   
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Similarly, invasion through Matrigel-coated transwells was profoundly reduced in 
MCF10A-RictorZFN cells as compared to parental MCF10A cells (Figure 11J). Under 
these conditions, there were a similar number of viable cells remaining in the upper 
transwell chamber after 24 hours of culture of both MCF10A and MCF10A-RictorZFN 
cells (Figure 12D), suggesting that cell death may not be the primary reason 
underlying the reduced ability of MCF10A-RictorZFN cells to migrate/invade in these 
transwell assays, but rather that cell invasion, per se, is decreased in the absence of 
Rictor. Collectively, these data demonstrate that Rictor promotes MEC invasion and 
migration, two processes necessary for mammary ductal lengthening and branching.  
Akt activation, while necessary for normal branching morphogenesis, is not 
sufficient to rescue morphogenesis, survival, and motility defects in the 
absence of Rictor 
Because Rictor loss reduced P-Akt S473, we tested the hypothesis that Akt 
phosphorylation by Rictor-regulated mTOR complex 2 is necessary for survival and 
morphogenesis of MECs. Adenoviral expression of myristoylated Akt1 (Ad.Aktmyr) was 
used to express a membrane-localized (and thus, constitutively active) variant of Akt1. 
Indeed, expression of this Akt variant in mammary epithelium delays involution and 
the onset of apoptosis in vivo [38]. Additionally, we repeated experiments using an 
alternative adenoviral, constitutively active Akt construct Ad.Aktmyr or Ad.AktDD 
restored P-Akt S473 in Ad.Cre-infected RictorFL/FL PMECs (Figure 13A, 14A).  
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Figure 13. Akt activation is insufficient to rescue Rictor-deficient MEC survival, 
branch formation and invasion. A-C. PMECs and organoids from RictorFL/FL mice were 
co-infected with Ad.Cre and either Ad.LacZ or Ad.Aktmyr.  A. Western analysis of PMEC 
lysates. B. Organoids photographed after 10 days in Matrigel culture. Average number 
of branches/organoid ± S.D. (right panel) are shown. N = 20 independent organoids from 
5 independent mice. Midline values indicate average (data points = averages from 
individual experiments), whiskers indicate S.D., Student’s T-test. C. Colony size of 
organoids measured in pixel area. N = 20 independent organoids from 5 independent 
mice, average ± S.D., Student’s T-test. D-E. PMECs and organoids from WT mice 
treated 3-7 days with 5J8 Akt inhibitor or DMSO. D. Western analysis of PMECs after 3 
days treatment with 5J8. E. Organoids photographed after 10 days in DMSO or 5J8. 
Average number of branches/organoid ± S.D. (left panel) are shown.  Midline values 
indicate average (data points = averages from individual experiments), whiskers indicate 
S.D., Student’s T-test. Organoid size measured in pixel area shown in right panel 
Student’s T-test. N = 23 independent organoids from 6 independent mice. F-G. PMECs 
from RictorFL/FL mice were co-infected with Ad.Cre and either Ad.LacZ or Ad.Aktmyr. F. 
PMECs were assessed by TUNEL analysis. Representative images are shown. Average 
percent TUNEL+ nuclei (red) per total nuclei (DAPI, blue) was calculated. Individual cell 
isolates (N = 5, analyzed in duplicate) are represented by each data point. Midlines 
values are average percentage of TUNEL+ nuclei ±S.D., indicated by whiskers, 
Student’s T-test. G. Transwell migration of PMECs at 24 hours. N = 6 independent cell 
isolates per condition, analyzed in duplicate, Student’s T-test.  
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Surprisingly, RictorFL/FL organoids infected with Ad.Cre + Ad.Aktmyr or Ad.AktDD were 
morphologically similar, and harbored little to no statistically significant difference in 
the numbers of branches compared to those infected with Ad.Cre alone (Figure 13B, 
14B). Further, size of Rictor-deficient organoids was not fully rescued by expression of 
Ad.Aktmyr or Ad.AktDD (Figure 13C, 14C).  We found that blockade of Akt using the 
allosteric Akt inhibitor 5J8 blocked Akt phosphorylation at S473 (Figure 13D), reduced 
the number of branches per organoids, and reduced organoid size by nearly 50% 
(Figure 13E). These data suggest that while Akt is necessary for mammary branching 
and growth, restoring Akt function is not sufficient to completely rescue defects caused 
by loss of Rictor/mTORC2 function. Indeed, expression of Ad.Aktmyr did not reduce the 
number of Rictor-null PMECs undergoing cell death (Figure 13F), and did not 
increase the number Rictor-null PMECs invading through Matrigel-coated transwells 
(Figure 13G). Taken together, these observations suggest Rictor is necessary for Akt 
phosphorylation in MECs, but that Akt is not the primary effector of mTORC2 that 
regulates MEC survival, invasion, and side branching. Thus, while Akt is necessary for 
proper mammary epithelial morphogenesis, it is not sufficient to compensate for loss 
of Rictor/mTORC2 function.  
Protein kinase C (PKC) - activates the small GTPase Rac1 downstream of 
Rictor 
Previous studies showed that mTORC2 phosphorylates PKC [47]. Consistent 
with these findings, Rictor loss reduced P-PKCα in PMECs, as well as total PKCα 
(Figure 15A).  
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Figure 14. Akt activation is insufficient to rescue Rictor-deficient MEC branching ex 
vivo. A-C. PMECs and organoids from RictorFL/FL mice were coinfected with Ad.Cre and 
either Ad.LacZ or Ad.AktDD. A. Western analysis of PMEC lysates. B. Organoids 
photographed after 10 days in Matrigel culture. Average number of branches/organoid ± 
S.D. (right panel) is shown. N = 7 independent organoid isolates, analyzed in triplicate. 
Midline values indicate average, whiskers indicate S.D., Student’s T-test. C. Colony size of 
organoids (± S.D.) measured in pixel area. N = 7 independent organoid isolates, analyzed 
in triplicate, Student’s T-test. 
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We also observed decreased P-PKC by IF in mammary gland sections from 6-
week-old RictorMGKO mice, as compared to RictorWT controls (Figure 17A).  Adenoviral 
PKCα expression rescued P-PKC in Rictor-null PMECs (Figure 15B), rescued 
branching morphogenesis in Rictor-null organoids (Figure 15C) and increased Rictor-
null organoid size (Figure 15D). Similar to what was seen in mouse PMECs, P-PKC 
and total PKCα was diminished in MCF10A-RictorZFN cells relative to parental 
MCF10A (Figure 15E). Restoration of PKC by adenoviral transduction increased P-
PKC in both parental MCF10A and MCF10A-RictorZFN cells (Figure 15F). Rac1, a 
small GTPase involved in actin cytoskeletal dynamics, is necessary for migration of 
many breast cancer cell lines, regulates apical polarity in MECs, and is a downstream 
effector of mTORC2 signaling. Importantly, Rac1 is also a known effector of PKC in 
MECs [88-90], but the linear relationship between Rictor, PKC, and Rac1 in MECs is 
currently unknown. We examined Rac1 activation in MCF10A cells using agarose 
beads conjugated to recombinant p21-activated kinase binding domain (PBD), which 
specifically binds to active GTP-bound Rac. Western analysis to detect Rac1 in PBD 
pull-downs revealed decreased Rac-GTP in MCF10A-RictorZFN cells as compared to 
parental MCF10A (Figure 15G). However, Ad.PKC increased Rac-GTP in Rictor-null 
cells, confirming that PKC activates Rac downstream of Rictor. Additionally, 
Ad.PKC increased invasion of MCF10A-RictorZFN cells through Matrigel-coated 
transwells (Figure 15H), and significantly reduced apoptosis in MCF10A-RictorZFN, as 
measured by Annexin V-FITC staining (Figure 15I).  
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Figure 15. Loss of PKC-mediated Rac activation in the absence of Rictor. A-D. 
RictorFL/FL PMECs and organoids were infected with the indicated adenoviruses. A-B. 
Western analysis of PMEC lysates. Quantitation was performed using Image J software 
and numbers represent P-PKCα bands normalized to total PKCα levels. C. Organoids 
photographed after 10 days in Matrigel culture. Average number of branches/organoid 
±S.D. indicated below panels. N = 3 independent organoid isolates/condition analyzed 
in triplicate, Student’s T-test. D. Average colony size of organoids measured in pixel 
area ± S.D. N = 3 independent organoid isolates/condition, analyzed in triplicate, 
Student’s T-test. E. Western analysis of MCF10A parental and RictorZFN lysates. 
Quantitation was performed using Image J software and numbers represent P-PKC 
band normalized to actin for each sample. F-I. MCF10A parental and RictorZFN cells 
were infected with Ad.RFP or Ad.PKC. F. Western analysis of MCF10A parental and 
RictorZFN lysates, 48 hours post-infection. Quantitation was performed using Image J 
software and numbers represent P-PKC band normalized to actin for each sample. G. 
GST-Pak-PBD effector pull-downs followed by western analysis for Rac performed 48 
hours post-infection. Quantitation was performed using Image J software. Numbers in 
upper panel represent Rac-GTP levels in MCF10A-RictorZFN compared to MCF10A 
parental control. Lower numbers represent Rac-GTP levels normalized to total Rac for 
each sample. H. Cells were assessed for invasion through Matrigel-coated transwell 
filters. Cells were stained with crystal violet after 24 hours, and then imaged. Number of 
cells invading was quantitated in Image J. Values shown represent the average ± S.D., 
Student’s T-test. N = 2 independent experiments, analyzed in triplicate. I. Cells were 
assessed for Annexin V-FITC. Number of Annexin V-FITC+ per total number of cells 
was quantitated in Image J, Student’s T-test. N = 2 independent experiments, analyzed 
in triplicate. J. MCF10A parental cells were assessed for invasion through Matrigel-
coated transwell filters in the presence of PKCα inhibitor GO6976. Cells were stained 
with crystal violet after 24 hours, and then imaged. Number of cells invading was 
quantitated in Image J. Values shown represent the average ± S.D., Student’s T-test. N 
= 2 independent experiments, analyzed in quadruplicate. 
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A pharmacological PKC inhibitor profoundly decreased invasion of parental MCF10A 
cells through Matrigel-coated transwells (Figure 15J), providing validation that PKCα is 
necessary for MEC motility.  These data suggest Rictor-mediated PKC signaling in 
MECs controls Rac1 activation, branching morphogenesis, cell survival and motility. 
Restoring Rac activity rescues branching morphogenesis, survival, and motility 
induced by loss of Rictor 
To confirm the role of Rictor in Rac1 activation in vivo, we examined mammary 
epithelium in situ for GTP-bound Rac1 using a glutathione-S-transferase (GST)-PBD 
fusion protein as a probe for Rac-GTP. IF detection of GST-PBD binding was 
decreased in RictorMGKO mammary glands compared to RictorWT (Figure 16A, B, 
17B). Importantly, IF detection of GST-PBD binding in WT PMECs was abolished by a 
pharmacological Rac1 inhibitor (Figure 16C, 17C), confirming the specificity of the 
assay for detection of Rac1-GTP. In contrast to the abundant Rac1-GTP detected in 
WT PMECs, RictorFL/FL PMECs infected with Ad.Cre displayed a 10-fold decrease in 
GST-PBD binding to Rac-GTP relative to Ad.LacZ infected controls (Figure 16C, 
17C). Phalloidin staining revealed cortical actin overlapping with GST-PBD binding in 
Ad.LacZ-infected RictorFL/FL PMECs (Figure 17D). However, Ad.Cre-infected 
RictorFL/FL PMECs showed increased formation of actin stress fibers, bearing no 
overlap with GST-PBD. Constitutively active Rac1 (Ad.caRac1) expression (Figure 
16D) restored GST-PBD binding in Rictor-null PMECs (Figure 16E), suggesting that 
Rictor is necessary for Rac1-GTP in PMECs.   
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Ad.caRac1 was used to determine if restoration of Rac1-GTP could rescue 
invasion in Rictor-null MECs. Ad.caRac1 increased invasion 2.5-fold over Ad.LacZ in 
Rictor-null PMECs (Figure 16F). P-Akt S473 was unaffected by caRac1 (Figure 16D), 
suggesting that while Akt and Rac1 are both effectors of Rictor-dependent signaling, 
they exist in two separable pathways in MECs. Despite having no impact on P-Akt, 
Ad.caRac1 decreased cell death in Rictor-null PMECs (Figure 16G, 17E), suggesting 
that Rictor-dependent Rac1-GTP is necessary for PMEC survival. Ad.caRac1 also 
rescued branching morphogenesis of Rictor-deficient organoids (Figure 16H). 
Conversely, Rac inhibition using a pharmacologic Rac1 inhibitor decreased organoid 
size and branching in WT organoids (Figure 16I), confirming that Rac1 is necessary 
for mammary epithelial branching morphogenesis. Thus, Rictor is required for Rac1-
GTP signaling, and restoration of Rac1 activity rescued branching morphogenesis and 
survival of Rictor-deficient PMECs. To determine if Rictor/mTORC2-mediated 
branching morphogenesis and ductal outgrowth are dependent on PKCα/Rac versus 
Akt, we transduced PMEC from RictorFL/FL mice with control Ad.GFP versus Ad.Cre in 
the presence or absence of Ad.PKCα, Ad.caRac, or Ad.Aktmyr and transplanted them 
into the cleared inguinal mammary fat pads of 4-week-old recipient female mice. We 
harvested mammary glands from these animals 6 weeks post-transplantation and 
assessed epithelial architecture and branching morphogenesis in whole-mount 
preparations. Consistent with data from MMTV-Cre/RictorFL/FL mice, transplanted 
Rictor-deficient MEC produced structures characterized by shortened ductal 
outgrowths with fewer branches relative to GFP controls (Figure 16J, K). 
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Figure 16. Rictor-mediated Rac activity is necessary and sufficient for mammary 
branching morphogenesis ex vivo. A. In situ detection of GTP-bound Rac via IF 
detection of GST-PBD (red; nuclei stained with DAPI, blue) on mammary gland sections 
from 6-week old mice. N = 6 independent fields analyzed in sections from 3 independent 
mammary gland sections/genotype. B. Quantitation of average percent red fluorescence 
(Rac-GTP) relative to blue (DAPI) on mammary gland sections from 6 week old virgin 
RictorWT and RictorMGKO mice, ± S.D. C. Cells were probed with GST-PBD (red) and 
counterstained with DAPI (blue). GST alone (not conjugated to PBD) was used as a 
negative control. GST-PBD+ fraction of total PMECs was counted and average ± S.D. 
shown. N = 15 fields/condition. D-I RictorFL/FL PMECs infected with Ad.Cre or Ad.LacZ 
(±Ad.caRac1) and analyzed. D. Western analysis of PMEC lysates. E. Cells were probed 
with GST-PBD (green) and counterstained with phalloidin (red). F. Transwell invasion 
assays were performed. Invading cells were visualized with crystal violet and counted 
±S.D. N = 6 independent isolates, analyzed in duplicate, Student’s T-test. G. PMECs were 
assessed by TUNEL analysis. N = 3 independent cell isolates, analyzed in duplicate. 
Representative images shown. Average percent TUNEL+ nuclei per total epithelial nuclei 
quantified. Midline values indicate average, whiskers indicate S.D., Student’s T-test. H. 
RictorFL/FL organoids were infected Ad.Cre or Ad.LacZ (±Ad.caRac1) prior to embedding, 
and were photographed after 10 days in Matrigel culture. Right panel shows average 
number of branches per organoid. Each data point is the average branches per colony 
from individual isolates, analyzed in triplicate. Midlines are the average of all isolates, 
whiskers indicate S.D., Student’s T-test.  N = 6. I. WT organoids were cultured ±Rac 
inhibitor for 10 days. Number of branches per organoid quantified. Right panel shows 
average organoid size ±S.D. J-L. PMECs from RictorFL/FL mice were tranduced with control 
Ad.GFP versus Ad.Cre in the presence or absence of Ad.PKCα, Ad.caRac, or Ad.Aktmyr. 
PMECs were transplanted into the cleared inguinal fat pads of 4-week-old recipient female 
mice. Mammary glands were harvested six weeks post-transplantation and epithelial 
architecture and branching morphogenesis in whole-mount preparations was assessed. J. 
Whole-mount preparations from indicated transplanted glands. K. Quantitation of average 
number of branches ± S.D., Student’s T-test. Representative images shown from N=2 
independent experiments. L. Western analysis of lysates from donor PMECs. 
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Restored PKCα or Rac activity (Figure 16J, K) rescued these defects and produced 
epithelial outgrowth that resembled endogenous epithelium in contralateral controls 
(Figure 17F). Consistent with our ex vivo organoid culture analyses restored Akt 
activity was unable to fully rescue defects produced by loss of Rictor (Figure 16J, K). 
These data suggest that Rictor/mTORC2-dependent mammary epithelial 
morphogenesis relies primarily upon downstream activation of PKCα and Rac-
GTPase. 
Rapamycin-mediated inhibition of mTORC1 and mTORC2 mimics loss of 
Rictor/mTORC2 
Rapamycin is a pharmacologic inhibitor of mTOR originally thought to 
preferentially inhibit mTORC1 over mTORC2. However, sustained rapamycin 
treatment impairs both mTORC1 and mTORC2 in a cell type-dependent manner [66, 
91-93]. Consistent with this idea, acute rapamycin treatment for 1 hour (1 h) 
decreased P-S6 (an mTORC1 effector) but not P-Akt (an mTORC2 effector), whereas 
sustained rapamycin treatment (24 h) decreased both P-S6 and P-Akt S473 (Figure 
18A). Rapamycin treatment for 10 days significantly decreased branching 
morphogenesis and organoid size in WT organoids (Figure 18B). Although PMEC 
survival was not affected by acute rapamycin treatment, cell death increased after 24 
h with rapamycin (Figure 18C).  
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Figure 17. Rictor-mediated PKCα activation controls acinar formation and motility 
in human and mouse MECs. A. Immunofluorescent detection of P-PKCα in mammary 
gland sections from 6 week old virgin RictorWT and RictorMGKO mice. B. In situ detection of 
GTP-only control (no PBD) via IF detection of GST-PBD (red; nuclei stained with DAPI, 
blue) on mammary gland sections from 6-week old mice. C. WT PMECs cultured ± Rac 
inhibitor or RictorFL/FL PMECs infected with Ad.LacZ or Ad.Cre were assessed for GTP-
bound Rac via IF detection of GST-PBD (red; nuclei stained with DAPI, blue). D.  
RictorFL/FL PMECs infected with Ad.Cre or Ad.LacZ were probed with GST-PBD (green) 
and counterstained with phalloidin (red). Representative images are shown. E. RictorFL/FL 
PMECs infected with Ad.Cre or Ad.LacZ (±Ad.caRac1) were analyzed for TUNEL. F. 
Whole mount analysis of endogenous mammary glands harvested from WT recipient 
mice. 
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Proliferation of WT PMECs, as measured by BrdU incorporation, was unaffected 
by acute (30 min) or sustained (24 h) pre-treatment with rapamycin (Figure 18D). The 
effects of sustained rapamycin treatment, including reduced MEC survival, branching 
morphogenesis formation, and diminished organoid size were similar to the effects 
achieved by Rictor ablation in MECs. Also similar to what was seen with Rictor-
deficient MECs, the phenotypic effects of rapamycin treatment were rescued by 
Ad.PKC (Figure 18E) and Ad.caRac1 (Figure 18F), including rescue of branching 
morphogenesis and colony size.  Ad.caRac1 also rescued rapamycin-mediated 
inhibition of cell motility (Figure 18G). Because the mTOR inhibitor rapamycin impairs 
mTORC1 and mTORC2, and recapitulates the morphological and molecular effects of 
Rictor ablation in MECs, these results suggest that Rictor is acting in complex with 
mTOR to regulate MEC survival, motility, and branching morphogenesis, supporting a 
role for mTORC2 in the developing mammary gland. However, these findings do not 
rule out the contribution of mTORC1 to mTOR-mediated mammary morphogenesis. 
Raptor/mTORC1 loss produces relatively mild defects in mammary branching 
morphogenesis and epithelial growth in vivo and ex vivo 
To understand how mTORC1 participates in mammary morphogenesis, we 
infected PMECs harvested from female RaptorFL/FL mice [19] with Ad.Cre. Western 
analysis confirmed loss of Raptor and decreased P-S6 in serum-deprived cells 
(Figure 19A).  
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Figure 18. mTOR inhibition with rapamycin decreases MEC survival, motility and 
acinar formation, which are rescued by enforced Rac activity A-G. WT PMECs and 
organoids were cultured in DMSO vehicle or rapamycin. PMECs were cultured 0, 0.5, or 
24 hours. Organoids were cultured 10 days in Matrigel in the presence of DMSO or 
rapamycin. A. Western analysis of PMEC lysates. Quantitation was performed using 
Image J software and numbers represent P-Akt, P-S6, or P- lized to 
total Akt, S6, or PKCα levels. B. WT organoids photographed after 10 days in Matrigel 
culture. Average organoid size scored as average pixel area ± S.D., Student’s T-test, N 
= 6 epithelial isolates, each analyzed in triplicate. C. TUNEL analysis of PMECs. 
Average percent TUNEL+ nuclei per total PMEC nuclei ± S.D. is shown, Student’s T-
test. N = 3 independent cell isolates, analyzed in duplicate. D. PMECs were labeled with 
BrdU after initial pre-treatments with rapamycin for 0.5 hours or 24 hours. Average 
percent BrdU+ nuclei per total nuclei ± S.D. is shown, One-way ANOVA, N = 3 
independent cell isolates, analyzed in triplicate. E-F. Organoids were infected with 
Ad.LacZ or Ad.PKC (panel E) or Ad.caRac1 (panel F) prior to embedding in Matrigel 
plus rapamycin or DMSO. Average number of branches/colony is shown below each 
image. Average organoid size scored as average pixel area ± S.D., Student’s T-test (E) 
and one way ANOVA (F), N = 6 epithelial isolates, each analyzed in triplicate. G. 
Confluent PMEC monolayers were scratch-wounded, cultured in rapamycin or DMSO, 
and imaged at 24 hours. Total wounded area remaining after 24 h was measured. 
Values shown are the average wound area remaining ± S.D. N = 3 independent cell 
isolates, analyzed in triplicate. 
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However, P-Akt S473 was unaffected by Raptor ablation, confirming that genetic 
ablation of Raptor causes selective inhibition of mTORC1, while Rictor ablation inhibits 
mTORC2. RaptorFL/FL mammary organoids infected with Ad.LacZ formed multi-
branched colonies, as expected (Figure 19B). Surprisingly, infection with Ad.Cre did 
not affect branching morphogenesis in RaptorFL/FL organoids, the number of branches 
per organoid, or colony size (Figure 19B).  Additionally, Raptor ablation had no 
significant impact on PMEC migration in wound healing assays (Figure 19C). 
RaptorFL/FLMMTV-Cre (RaptorMGKO) mice were used to assess the impact of 
Raptor ablation on mammary morphogenesis in vivo. IHC detected Raptor and the 
mTORC1 effector P-S6 in RaptorWT mammary glands at 10 weeks of age but did not 
detect P-S6 in age-matched RaptorMGKO mice (Figure 19D). Immunofluorescent (IF) 
staining for cytokeratin (CK)-8 and CK14, molecular markers of luminal and 
myoepithelial MECs, respectively, confirmed that Raptor loss did not affect the relative 
spatial organization of luminal and myoepithelial MECs (Figure 20A – upper panel). 
Additionally, no alterations in localization or staining pattern of ZO-1 were observed 
(Figure 20A – lower panel). Proliferation, as measured by IHC for Ki67, was 
significantly decreased in RaptorMGKO ducts in 6-week old mice (Figure 19D), but not 
in TEBs (Figure 20C).  By 10 weeks, however, proliferation in ducts had recovered to 
levels seen in RaptorWT (Figure 19D). TUNEL analysis revealed similar ratios of 
TUNEL+ MECs in ducts from RaptorMGKO and RaptorWT samples harvested from 6 and 
10 week old animals (Figure 19D) and in TEBs from 6 week- old animals (Figure 
20B).  
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Figure 19. Unlike mTORC2, mTORC1 is dispensable for MEC survival and branching 
morphogenesis. A-C. RaptorFL/FL PMECs and organoids were infected with Ad.Cre and 
Ad.LacZ, and cultured 10 days. A. Western analysis of PMECs cultured in the absence of 
serum. Quantitation was performed using Image J software and numbers represent P-Akt 
or P-S6 bands normalized to total Akt or S6 levels. B. Organoids were infected with Ad.Cre 
or Ad.LacZ photographed after 10 days in Matrigel culture. Representative images are 
shown. Average number of branches/organoid for each group is shown below the image. 
Average organoid size (pixels) ± S.D. is shown, Student’s T-test. N = 6 independent 
organoid isolates, analyzed in triplicate. C. PMECs from RaptorFl/FL mice were infected with 
Ad.LacZ or Ad.Cre, grown to confluence and scratch-wounded. Monolayers were imaged. 
Total wound area remaining was measured 24 hours after wounding. Values shown are the 
avg ± S.D. N=6 per time point, Student’s T-test. D-E. Mammary glands from virgin female 
mice at 10 weeks of age were analyzed. N = 10 mice per genotype at each time point. 
Statistical analysis performed with Student’s T-test. D. IHC for Raptor, P-S6, Ki67+, and 
TUNEL+ nuclei in mammary glands of 6-week old mice. Representative images are shown. 
Scale bars = 50 µm. Average percent Ki67+ nuclei and TUNEL+ nuclei (± S.D) per total 
epithelial nuclei was determined E. Whole mount hematoxylin staining of mammary glands. 
Representative images are shown. LN = lymph node. The ductal length beyond the lymph 
node was measured. Average length (in microns) ± S.D. is shown. The number of T-shaped 
side branches was enumerated. Values shown represent average number of side branches 
± S.D.  
 
71 
 
Consistent with these observations, only mild defects in side branching and ductal 
length were found in mammary glands from 6-week old RaptorMGKO mice (Figure 
19E), and these were resolved by 10 weeks of age.  
Taken together, these results demonstrate that mTOR uses Rictor to activate 
PKCα/Rac1-dependent survival, motility, and branching morphogenesis in the 
mammary epithelium and that Rictor does not rely fully on Akt signaling to promote 
ductal morphogenesis in the breast.  
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Figure 20. Unlike mTORC2, mTORC1 is dispensable for MEC survival in 
vivo. A. IF for CK8, CK14 and ZO-1 in mammary gland sections. B. IHC for Ki67 
or TUNEL in TEBs from 6-week-old wild-type RaptorWT mice and RaptorMGKO 
mice. Average percent Ki67+ and TUNEL+ nuclei (± S.D.) was determined, 
Student’s T-test. 
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Discussion  
 Postnatal mammary epithelial morphogenesis requires precise coordination of 
cell proliferation, apoptosis, differentiation, and motility in order to turn rudimentary 
epithelial buds into an organized, branched ductal network permeating the entire 
mammary fat pad by the end of puberty [34, 35]. mTOR is a central regulator of 
proliferation, apoptosis, differentiation, and motility, integrating numerous upstream 
signals to generate the desired biological outcome. Therefore, we assessed how 
mTOR signaling contributes to mammary morphogenesis. We found that 
pharmacologic mTOR inhibition reduced the size and branching complexity of 
mammary organoids in culture, phenotypes recapitulated by mTORC2 loss of function 
via Rictor ablation, but not upon mTORC1 inhibition through Raptor ablation. We also 
observed a disorganized epithelial architecture and stromal thickening around TEB 
upon tissue-specific Rictor ablation. The MMTV-Cre model has been reported to be 
leaky, leading to expression in tissues other than luminal mammary epithelium [94] 
thus it is possible that some of these defects may be due to loss of Rictor in stromal 
components. Alternatively, changes in basal epithelium may be a secondary effect of 
luminal cell misolocalization in the absence of Rictor, or Rictor expression in the 
luminal compartment may regulate expression and function of mTOR signaling 
intermediates in the basal cell layer through an indirect, juxtacrine signaling 
mechanism. We are actively investigating the role of Rictor/mTORC2 in luminal versus 
basal epithelium in our ongoing research.  
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As our epithelial branching and survival phenotypes were recapitulated in the ex vivo 
stroma-free organoid culture model, however, it is likely that the effects on stroma are, 
at least in part, secondary to the loss of Rictor in epithelium. 
Genetic inhibition of mTORC2 also reduced ductal branching and lengthening in 
vivo, diminished P-Akt and P-PKCα, and impaired activation of the GTPase Rac1. Akt 
restoration only modestly enhanced branching morphogenesis in Rictor-deficient 
mammary organoids and was not sufficient to rescue cell survival or PMEC invasion 
through Matrigel. However, Akt inhibition did decrease organoid branching and colony 
size suggesting that Akt provides a critical signal in growth control, but is not sufficient 
to drive branching morphogenesis in the absence of Rictor. This is consistent with the 
data from our analysis of transplanted Rictor-deficient/AktMyr expressing MEC in vivo 
and with the phenotype of Akt1 deletion, which did not affect mammary epithelial cell 
differentiation but did impair lactation [36]. Deletion of Akt1 and one allele of Akt2 
enhanced this defect [95, 96]. Moreover, Akt activation did not completely inhibit 
luminal apoptosis during MCF10A acinar morphogenesis in culture [97], suggesting 
that other factors also regulate cell survival during normal mammary epithelial 
development. In contrast to Akt, restoration of PKCα signaling to Rac1, or Rac1 
activation independently of upstream signals, fully rescued all phenotypes resulting 
from Rictor loss in culture and in transplanted Rictor-deficient MEC in vivo, suggesting 
that Rictor-dependent mTORC2 is essential for PKCα-Rac1 signaling to drive 
mammary morphogenesis. While not directly tested here, at least one additional study 
has elucidated mechanisms downstream of Rac1 that can control cell survival.  
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One report using lymphoma cells demonstrated direct inhibition of apoptosis through 
Rac1-stimulated phosphorylation of the Bcl-2 family member, Bad, which occurred in 
an Akt-independent manner [98]. We observed a modest decrease in cell viability 
upon prolonged treatment with the Rac1 inhibitor in organoid culture coupled with the 
decreased branch extension, consistent with previous studies that also reported 
regulation of branching initiation and extension via PI3K-mediated Akt and Rac1, 
respectively [99]. 
Interestingly, levels of mTORC1 target P-S6 are elevated in MEC upon Rictor loss 
relative to controls. This could reflect shift of mTOR kinase to complex 1 in the 
absence of a stable mTORC2 complex. It will be of great interest to track mTOR 
kinase association with the two complexes over the course of mammary epithelial 
development to better understand its functions. Activation of the Akt signaling pathway 
upon mTOR inhibition via a negative feedback loop has been observed in many cell 
types, including breast cancer cell lines (Reviewed in [100]). In our study, rapamycin 
preferentially inhibited mTORC1 upon acute treatment (e.g. reduction in P-S6 without 
affecting P-Akt-S473 levels) and as prolonged treatment inhibited both complexes 
(e.g. reduction in both P-S6 and P-Akt-S473). These data are consistent with the 
observation that rapamycin is an effective inhibitor for activity of both complexes in 
many cell types [10], including MECs. The differences in response to rapamycin 
between normal MECs and breast cancer cell lines could be due to differences in 
insulin-like growth factor receptors (IGFRs), which are expressed at higher levels in 
cancer cells and mediate feedback to Akt upon mTOR inhibition (Reviewed in [100-
102]). 
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Given the known roles of mTORC1 in cell growth, metabolism, and protein and 
lipid synthesis [76], it was surprising that Raptor loss produced only a transient delay 
in ductal lengthening. It is possible that other signaling pathways may compensate for 
loss of mTORC1 function in Raptor-deficient mammary epithelium, such as RSK-
mediated activation of S6 [103, 104]. However, we observed similar decreases in 
cellular proliferation in the absence of Raptor and Rictor expression at 6 weeks that 
recovered by 10 weeks, suggesting that MEC proliferation may rely on both mTORC1 
and mTORC2. Decreased MEC proliferation upon genetic mTORC1 ablation is 
consistent with other reports of rapamycin-mediated cell growth inhibition in lactating 
mouse mammary explants, in lactating mice, and in milk-producing HC11 cells. Based 
on these previous studies, it will be important to determine the effects of Raptor and 
Rictor ablation on growth, differentiation, and milk production in alveolar mammary 
epithelium during pregnancy and lactation in vivo.  
The PI3-kinase (PI3K)/mTOR pathway is aberrantly activated up to 60% of clinical 
breast cancers, facilitating tumor cell growth, survival, metabolism, and invasion [105, 
106]. Moreover, increased PI3K activity in MMTV-Cre/PTENFL/FL mice increases 
mammary epithelial branching and decreases apoptosis during pubertal development 
[107], suggesting that PI3K signaling is important in branching and survival in the 
breast. This idea is consistent with the phenotype produced by MMTV-Cre-driven 
Rictor loss, in which loss of a PI3K pathway mediator produces decreased branching 
and survival.  
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While inhibitors of mTORC1 show limited clinical efficacy as single agents, anti-PI3K 
agents combined with dual mTORC1/2 inhibitors appear to be more effective [67, 108-
110], underscoring the clinical relevance of mTORC2 in breast cancer. Importantly, 
these recent clinical observations parallel the data shown here demonstrating that 
mTORC2 inhibition due to either sustained rapamycin treatment or to Rictor deletion 
profoundly affected the complex series of events driving mammary morphogenesis, 
and these mTORC2-dependent processes occur in a manner unique and separable 
from mTORC1. Interestingly, preferential targeting of mTORC2 versus mTORC1 
reduced breast cancer cell motility and survival in culture and in vivo [55, 68], and 
Rictor knockdown suppressed anchorage-independent growth of MCF7 breast tumor 
cells [111].  
 Although at least one report suggests elevated Rictor levels correlate with higher 
overall and recurrence-free survival [112], Rictor overexpression was observed in 
clinical invasive breast cancer specimens relative to normal breast tissue, as well as in 
lymph node metastases [55], supporting the clinical relevance of mTORC2 in invasive 
breast cancer. Given our findings that Rictor/mTORC2 is required in the normal 
mammary epithelium for PKC-Rac1 activation which drives MEC survival, motility, 
and invasion, it will be interesting to determine if the mTORC2-PKC-Rac signaling 
axis is used by breast cancer cells to drive metastasis. If so, mTORC2-specific 
targeting or PKC inhibition could represent potential therapeutic strategies to limit 
metastatic spread of breast tumors, and to limit survival of disseminated tumor cells.   
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Although data shown herein are the first demonstration of mTORC2-mediated 
regulation of normal MEC migration and invasion, several lines of evidence suggest 
that cancer cells exploit Rictor-dependent signaling pathways to facilitate invasion and 
metastasis. For example, siRNA-mediated Rictor knockdown inhibited MCF7 and 
MDA-MB-231 breast cancer cell migration [55, 68]. Rictor knockdown inhibited 
transforming growth factor beta (TGFβ)-mediated epithelial-to-mesenchymal transition 
(EMT) in breast cancer lines [69]. In contrast to our findings that untransformed MECs 
use Rictor to activate PKC and Rac1-mediated invasion, breast cancer cells used 
Rictor to drive motility through protein kinase Cζ (PKCζ; [55]), integrin-linked kinase 
(ILK; [69]) and Akt [68]. Although Akt phosphorylation at S473 required 
Rictor/mTORC2 in primary MECs, restoring Akt function was not sufficient to rescue 
survival, motility, or branching morphogenesis in the absence of Rictor. Restoration of 
Rac1 activity, an essential regulator of mammary epithelial branching morphogenesis 
[81, 113] and a downstream effector of mTORC2 and PKC, rescued survival and 
migration defects induced by genetic mTORC2 inhibition. While not specifically linked 
to Rictor in breast cancer cells, Rac1-mediated invasion and metastasis of breast 
cancer cells has been reported previously [114-116]. Together, these data suggest 
that Rictor/mTORC2-dependent Rac signaling could promote breast cancer invasion, 
paralleling its function normal MEC branching morphogenesis. It is possible that 
breast cancer cells can engage multiple pathways (PKC, ILK, Akt, Rac, and others) 
to regulate tumor cell metastasis, and it is interesting to speculate that Rictor may lie 
at the intersection of each of these pathways. 
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In summary, our data demonstrate distinct, non-overlapping functions of mTORC1 
and mTORC2 in post-natal mammary morphogenesis. Whereas Raptor-dependent 
mTORC1 signaling regulates proliferation, Rictor-dependent mTORC2 is essential for 
cell survival, cell junctions, motility, and branching morphogenesis. These findings 
underscore the importance of understanding the distinct roles for mTORC1 and 
mTORC2 in normal physiology of the breast and in breast cancer in order to 
intelligently develop and administer mTOR-directed therapies.  
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Chapter III 
 
 RICTOR/MTORC2 DRIVES PROGRESSION AND THERAPEUTIC RESISTANCE 
OF HER2-AMPLIFIED BREAST CANCERS  
 
 
Abstract 
 
  Aberrant phosphatidyl inositol-3-kinase (PI3K)/Akt signaling occurs in nearly 60% 
of breast cancers through HER2 amplification, PIK3CA mutation, PTEN inactivation, 
or other mechanisms. The mTOR complexes mTORC1 and mTORC2 operate as 
activators (mTORC2) or effectors (mTORC1) of Akt, but mTORC2-specific roles in 
breast cancer remain elusive. Immunohistochemistry showed up-regulation of the 
mTORC2 obligate cofactor Rictor, but not the mTORC1 cofactor Raptor, in invasive 
breast tumors. Genomic gains in mTORC2 obligate cofactors correlated with 
decreased survival in breast cancer patients. Rictor loss in a mouse model of HER2-
amplified breast cancer decreased tumorigenesis, tumor cell proliferation and survival, 
and Akt-S473 phosphorylation. Similarly, Rictor loss in human HER2-amplified breast 
cancer cells decreased Akt-dependent cell survival. mTORC2 inhibition using Rictor 
knockdown or dual mTORC1/2 kinase inhibition increased lapatinib-induced cell killing 
in HER2-amplified breast cancers, including those with lapatinib resistance. Raptor 
loss decreased tumorigenesis but did not affect cell survival or Akt-S473 
phosphorylation in HER2-amplified breast cancer cells. Rac1-dependent cell motility, 
invasion, and metastasis were decreased upon loss of Rictor, but not Raptor, due to 
accumulation of the Rac inhibitor RhoGDI2 in Rictor-depleted cells.  
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Thus, HER2-amplified breast cancers use Rictor/mTORC2 to drive Akt and Rac 
signaling, warranting additional studies into mTORC2-specific inhibitors. 
Introduction 
  Breast cancer is the most common malignancy among western women. 
Approximately 20% of breast cancers exhibit overexpression of human epithelial 
growth factor receptor 2 (HER2), a marker of aggressive disease [117]. While HER2-
targeted therapies improve outcome for patients with HER2-amplified breast cancers, 
resistance to HER2 inhibitors often occurs, underscoring the need for increased 
understanding of the signaling pathways required for HER2-mediated transformation 
and malignancy [118]. HER2 activates the phosphoinositol-3 kinase (PI3K)/Akt 
signaling cascade, regulating tumor cell growth, survival, metabolism and motility.  
Targeting HER2 using antibodies (e.g., Herceptin) or tyrosine kinase inhibitors (e.g., 
lapatinib, neratinib) reduces PI3K/Akt signaling, resulting in decreased tumor cell 
growth and survival in HER2-amplified breast cancers. Although HER2-targeted 
treatments have improved the outcome for patients with HER2-positive breast 
cancers, primary or acquired resistance to HER2 inhibitors frequently occurs, 
accompanied by resurgent PI3K/Akt signaling. PI3K inhibitors block Akt activation and 
are being tested in HER2-amplified breast cancers. However, increasing evidence 
demonstrates that loss of negative feedback to PI3K, mitogen activated protein kinase 
(MAPK) and receptor tyrosine kinases resulting from PI3K inhibition dampens the net 
response to treatment [119]. Additionally, dose-limiting toxicities reported with PI3K 
inhibitors may limit its clinical utility.  
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Therefore, a greater understanding of signaling pathways both upstream and 
downstream of Akt is required if we are to effectively block Akt signaling in HER2-
amplified breast cancers. 
  Interestingly, the intracellular serine/threonine kinase mammalian target of 
rapamycin (mTOR) is unique in that it functions both to activate Akt, and to respond to 
activated Akt [120]. This dual functionality of mTOR is possible because mTOR exists 
in two structurally and functionally distinct complexes, defined by the cofactors 
associating with mTOR, and by their relative sensitivity to rapamycin. Specifically, 
Raptor is a required cofactor for rapamycin-sensitive mTORC complex 1 (mTORC1), 
which is activated downstream of PI3K/Akt and mediates cell growth, protein 
translation, and metabolism [19]. Rictor is a required cofactor for mTORC2, which 
controls cell survival, polarity, and cytoskeletal dynamics [121]. mTORC2 lies 
upstream of Akt, directly phosphorylating Akt at S473, an event necessary for maximal 
Akt activation and substrate specificity [16, 122]. Given that mTORC1 and mTORC2 
are comprised of distinct co-factors and phosphorylate distinct substrates, it is likely 
that mTORC1 and mTORC2 have distinct physiological roles, and their dysregulation 
may produce distinct pathological consequences. This notion is supported by recent 
findings that Rictor/mTORC2 is required during mammary gland development for 
ductal lengthening, secondary branching, mammary epithelial cell  (MEC) motility and 
MEC survival, while Raptor/mTORC1 is necessary for MEC proliferation [62] 
  Breast cancers often hijack many signaling pathways used by normal MECs to 
support tumor cell growth, survival, and metastasis [123, 124].   
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It is possible, therefore, that the unique effects of mTORC1 and mTORC2 in MECs 
are paralleled in breast cancers. The clinical efficacy of rapalogues (e.g., everolimus) 
in luminal breast cancers suggests that mTORC1 is important [70, 125]. Preclinical  
studies suggest this may also be true in HER2-amplified breast cancer cells [126]. 
However, increasing evidence suggests that targeting mTORC1 alone may increase 
IRS1-to-PI3K signaling and mTORC2-mediated Akt phosphorylation, ultimately 
dampening tumor response and promoting therapeutic resistance [66]. Clinical trials 
are currently investigating mTOR kinase inhibitors that would block both mTORC1 and 
mTORC2 [67]. However relatively little is known about the distinct role of mTORC2 in 
breast cancer formation, progression, and therapeutic response, despite its known 
role in activation of Akt, a key signaling node and critical effector of RTKs, including 
HER2. Interestingly, emerging evidence from prostate [63] and glioblastoma [64] 
models suggest a direct link between mTORC2 and PI3K-driven cancer progression. 
Preliminary studies show that genetic mTORC2 inhibition reduced breast tumor cell 
motility and survival in breast cancer cell lines [55, 68] [111].   
  We used a genetically engineered mouse model of HER2-amplified breast 
cancer to determine if Rictor/mTORC2 supports spontaneous tumor formation, and 
human HER2-amplified breast cancer cell lines to determine the impact of 
Rictor/mTORC2 on tumor cell survival and therapeutic response to HER2 inhibition. 
Our study uncovers a previously unreported role for Rictor/mTORC2 in HER2-
amplified breast cancers. 
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Materials and Methods 
Mice. All animals were housed under pathogen-free conditions, and experiments were 
performed in accordance with AAALAC guidelines and with Vanderbilt University 
Institutional Animal Care and Use Committee approval. RictorFL/FL mice (C57BL/6) 
were kindly provided by Dr. Mark Magnuson (Vanderbilt University) and have been 
previously described [23], and were inbred to FVB for >10 generations. MMTV-NIC 
mice (FVB) were purchased from the Jackson Laboratories, and have been previously 
described. All analyses of RictorFL/FL X MMTV-NIC mice were performed on age-
matched siblings in from FVB inbred crosses. RaptorFL/FL mice (C57BL/6) were 
purchased from the Jackson Laboratories (Bar Harbor, ME) and have been previously 
described [19]. All analyses of Rictor+/+ X MMTV-NIC were performed on age-matched 
siblings resulting from F1 (1:1, FVB:C57BL/6) intercrosses. 
Cell culture. All breast cancer cell lines were purchased from ATCC and cultured in 
DMEM plus antibiotics and 10% serum. MCF10A and MCF10A Rictor null cells were 
purchased from Sigma and transduced with lentiviral HER2-RFP particles or RFP 
control (GenTarget) and cultured in DMEM F12 plus insulin (4 mg/mL), cholera toxin 
(1 mg/mL), EGF (100 ug/mL), hydrocortisone (2 mg/mL) and 5% horse serum with 10 
ug/mL blasticidin. The Akt kinase inhibitor AZD5363 was purchased from 
SelleckChem. The in solution Rac1 inhibitor was purchased from 
Calbiochem/Millipore. The PKCα inhibitor, GO6976, was purchased from Tocris. 
Adenoviral particles Ad.caRac1, Ad.AktDD, Ad.PKCα were purchased from Vector 
Biolabs. Lapatinib resistant cell lines were generated as previously described [127].  
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Generation of stable knockdown cell lines. Rictor and Raptor lentiviral shRNA’s 
were purchased from Addgene. Plasmid DNA was transfected into 293 FT cells plus 
packaging vectors and cells were allowed to produce virus for 48 hours. Target breast 
cancer cells were infected every 4 hours for 2 days, then fresh media was added and 
cells were selected with puromycin (2mg/mL) for approximately 2 weeks. Stable 
knockdown of Rictor and Raptor was confirmed through western analysis for each 
independent shRNA construct. Knockdown cells were maintained under puromycin 
selection at a low passage. 
Reagents, siRNA and shRNA.  ARGHGDIB siRNA’s were purchased from Sigma 
using the following siRNA ID’s: SASI_Hs01_00125904 and SASI_Hs01_00125905. 
Prk5-myc-Rictor plasmid was a generous gift from Dr. Sarbassov. Short hairpin RNA’s 
for Rictor, Raptor, and scramble control were obtained from Addgene: 
- Rictor shRNA #1853, 1854  
- Raptor shRNA #1857, 1858  
- scramble shRNA #1864 
Western blotting. Cells were homogenized in ice-cold lysis buffer [50 mM Tris pH 
7.4, 100 mM NaF, 120 mM NaCl, 0.5% NP-40, 100 µM Na3VO4, 1X protease inhibitor 
cocktail (Roche)], sonicated for 10 s, and cleared by centrifugation at 4ºC, 13,000 x g 
for 10 min. Protein concentration was determined using the BCA assay (Pierce). 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes.  
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Membranes were blocked in 3% gelatin in TBS-T [Tris-buffered saline, 0.1% Tween-
20) for 1 h, incubated in primary antibody in 3% gelatin overnight, washed with TBS-T, 
incubated in HRP-conjugated anti-rabbit or anti-mouse IgG, washed with TBS-T, and 
then developed using ECL substrate (Pierce). The following primary antibodies were 
used: α-actin (Sigma-Aldrich; 1:10,000); phospho-cocktail (Cell Signaling; 1:250); 
AKT, S473 and T308 P-Akt (Cell Signaling; 1:1000); S6 and P-S6 (Cell Signaling; 
1:1000), Rictor (Santa Cruz; 1:250), Raptor (Cell Signaling; 1:500), RhoGDI2 (Spring 
Biosciences; 1:200), Rac1 (BD Biosciences; 1:1000), PKCα (Cell Signaling; 1:1000) 
and P-PKCα (Abcam; 1:1000) 
Transwell migration/invasion assays. Breast cancer cells (100,000) were serum 
starved overnight, counted and added to the upper chamber of uncoated (migration) 
or Matrigel-coated (invasion) transwells in starvation medium and incubated for 24 
hours.  Invasion was scored as described previously [84] by fixing cells on transwells, 
staining with 0.1 % crystal violet, and counting cells on the lower surface that 
migrated/invaded in response to growth medium plus 10% FBS or EGF (20 nm).  
Annexin V-FITC staining. Cells were trypsinized, counted, 5,000 cells were plated in 
96-well plates in triplicates and allowed to adhere to the plates overnight. 5 uL 
Annexin V-FITC (Invitrogen 807876) in 95 uL complete or serum-free DMEM was 
added to each well. Annexin V staining was monitored and images were captured at 6 
hours.  The number of Annexin V-FITC positive cells was quantitated using Image J 
and the percentage of Annexin V-FITC positive cells of total cells was calculated. 
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Caspase 3/7 Glo assay (Promega). 5,000 cells in 200 uL complete growth media 
were plated in 96-well plates and allowed to sit down overnight. The reagent and plate 
were allowed to equilibrate to room temperature, 175 uL media was removed (leaving 
25 uL behind), 25 uL Caspase Glo 3/7 reagent was added (1:1 ratio) and plate was 
incubated at room temperature for 1 hour. Plate was read on a plate reader to detect 
luminescence.  
Growth assays. For two-dimensional/monolayer growth assays, 5,000 cells were 
seeded in 12-well plates and allowed to grow over 14 days. Growth media 
(supplemented with 1 uM lapatinib, Rac inhibitor, PP242 or equal volumes of DMSO) 
was changed every 3 days. At 14 days, cells were washed with ice cold PBS, fixed 
with 10% formalin and stained with crystal violet. Plates were imaged and average 
colony area was quantified using the Odyssey imaging system and Odyssey software. 
For three-dimensional growth assay, 5,000 cells were resuspended in 100 uL Matrigel 
and plated in 96-well plates. After the Matrigel solidified, 100 uL growth media was 
added on top. Growth media (supplemented with 1 uM indicated inhibitors or equal 
volumes of DMSO) was changed every three days and colonies were photographed 
over the course of 14 days. Average colony area or average colony number was 
quantitated using Image J software.  
Human Tissue Microarray. Human tissue microarray (breast carcinoma with normal 
tissue controls) was purchased from Cybrdi (#CC08-10-001).  
Histological analysis. Tumors were resected and sections (5-m) were stained with 
hematoxylin and eosin. In situ TUNEL analysis was performed on paraffin-embedded 
sections using the ApopTag kit (Calbiochem).  
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IHC on paraffin-embedded sections or on human TMA’s was performed as described 
previously [83] using: Rictor (Santa Cruz Biotechnologies), Raptor (Abcam), Ki67 
(Santa Cruz Biotechnologies), P-S6 (Cell Signaling Technologies); P-Akt S473 (Cell 
Signaling Technologies); Rictor (Santa Cruz) Immunodetection was performed using 
the Vectastain kit (Vector Laboratories), AF488-conjugated anti-rabbit, or AF621-
conjugated anti-mouse (Life Technologies), according to the manufacturer’s 
directions.  
Xenograft experiments. Estrogen pellets (14 days extended release, 0.17 mg β 
estradiol; Innovative Research of America) were implanted subcutaneously into 3- to 
4-week-old female BALB/c athymic nude mice (Harlan Laboratories). Right and left 
inguinal mammary fat pads were injected with 106 MDA-MB-361 shScramble or 
shRictor cells in 100 μl growth factor–reduced Matrigel or 2x106 BT474 LR cells or BT 
LR shRictor cells. Tumors were measured with calipers twice weekly.  
Statistics. To assess statistical significance in experiments directly comparing an 
experimental group with a control group, Student’s unpaired, 2-tailed t test was used. 
To assess statistical significance in experiments in which multiple groups were 
compared across a single condition, 1-way ANOVA was used. To compare the 
response of 2 agents combined to either single agent alone, 2-way ANOVA was 
used. P < 0.05 was considered significantly different from the null hypothesis. 
Study approval. All animal experimentation was performed in AAALAC-approved 
facilities at Vanderbilt University Medical Center. All animal use protocols were 
reviewed and approved prior to experimentation by the Institutional Animal Care and 
Use Committee at Vanderbilt University. 
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Results 
Rictor expression is elevated in invasive breast cancers and correlates with 
decreased survival of breast cancer patients. 
  Because mTORC2 is a potent activator of Akt, while mTORC1 is a potent 
effector of Akt, we examined mRNA expression levels of obligate mTORC1 and 
mTORC2 cofactors in clinical breast cancer specimens curated by The Cancer 
Genome Atlas (TCGA), specifically examining tumors with genetic alterations in PI3K 
pathway genes, including HER2 gene amplification, PIK3CA activating mutations, and 
PTEN loss/mutation (Figure 21A). mRNA upregulation of mTORC2 cofactors 
RICTOR and MAPKAP1 (the gene encoding Sin1) occurred in nearly 20% of all breast 
tumor samples.  Specifically, upregulation of RICTOR and MAPKAP1 occurred in 
20/99 HER2-amplified tumors, 52/181 PIK3CA mutant tumors, and 35/149 PTEN-
altered tumors, supporting a potential role for mTORC2 in PI3K-driven breast cancers. 
Interestingly, genetic mTORC2 alterations rarely overlapped with each other. RPTOR 
mRNA upregulation was not detected (Table 2). Additionally, genomic gains of 
MAPKAP1 (P = 0.004) or RICTOR (P = 0.093) but not RPTOR, (P = 0.630) correlated 
with decreased survival in breast cancer patients (Figure 21B). Rictor and Raptor 
protein levels were assessed in clinical breast cancer tissue microarrays (TMAs) by 
immunohistochemistry (IHC). While Rictor was expressed below the level of detection 
in normal breast and ductal carcinoma in situ (DCIS) specimens (Figure 21C), Rictor 
was significantly upregulated in invasive breast carcinomas (IBCs), 37% of which 
scored positive for Rictor staining (Table 3).  
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In contrast, Raptor was expressed similarly in normal breast tissue, DCIS, and IBCs. 
Strikingly Rictor (but not Raptor) staining intensity was higher in grade II/III breast 
tumors as compared to what was seen in grade I/II tumors, suggesting that Rictor 
expression may be informative of aggressiveness and outcome in breast tumors, 
particularly those with PI3K pathway activating aberrations  (Figure 21D). These data 
suggest that Rictor expression may be informative of aggressiveness and outcome in 
breast tumors, particularly those with PI3K pathway-activating aberrations. Consistent 
with this notion, RICTOR genomic gains/amplifications occurred in 37/59 (63%) of the 
breast cancer cell lines assessed and reported by the Cancer Cell Line Encyclopedia 
(CCLE), versus RPTOR gains which occurred in 23/59 (39%) of all samples (Figure 
21E). Assessment of RICTOR and RPTOR mRNA levels by RT-qPCR revealed 
elevated expression of RICTOR in 8/9 (89%) of breast cancer cell lines assessed as 
compared to what was seen in untransformed MCF10A mammary epithelial cells, 
while 6/9 (66%) of breast cancer cell lines displayed increased RPTOR mRNA 
(Figure 21F). RICTOR expression was higher in HER2-amplified breast cancer cells 
as compared to luminal or basal-like. Rictor protein expression was observed in 
HER2-amplified cells, which also exhibited phosphorylation of Akt at S473, the 
mTORC2-specific site required for full AKT activation (Figure 21G). Collectively, these 
data indicate a potential role for Rictor and mTORC2 in human breast cancers, and 
suggest that HER2-amplified breast cancers in particular may rely on Rictor/mTORC2. 
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Figure 21. Rictor expression is elevated in human breast cancer. A-B TCGA-
curated breast cancers were assessed. A. HER2/PI3K/mTOR pathway genetic 
aberrations were assessed. B. Kaplan-Meier analysis of survival in patients with 2N or 
> 2N copies of the indicated genes. C-D. Representative images (C) and quantitation 
(D) of Rictor and Raptor IHC in human breast cancers by stage and grade. Arrows in 
C indicate Rictor positive cells.  E.  Rictor, Raptor and HER2-PI3K pathway alterations 
in the CCLE breast cancer cells. F-G Rictor and Raptor mRNA levels (F) and protein 
levels (G) in breast cancer cell lines compared to untransformed MCF10A cells.  
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  Rictor mRNA 
upregulation 
MAPKAP1 mRNA 
upregulation 
Rptor mRNA 
upregulation 
HER2-amp 6% (6/99) 14.1% (14/99) 0% 
PIK3CA mut  15% (27/181) 23.8% (25/181) 0% 
PTEN loss 13.4% (20/149) 10% (15/149) 0% 
Co-occurrence w/ PI3K 
pathway aberration 
(HER2-amp, PIK3CA 
mut, PTEN loss) 
13.4% 12.3% 0% 
Table 2. Upregulation of mTORC2 pathway components overlaps with HER2/PI3K 
pathway alterations.  Rictor and MAPKAP1 (the gene encoding Sin1) mRNA 
upregulation co-occurs with HER2/PI3K pathway alterations in TCGA-curated breast 
tumors (n=825). Rptor mRNA upregulation was not detected. 
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  Rictor negative Rictor positive Raptor negative Raptor 
positive 
DCIS/ 
normal 
100% (10/10) 0% (0/10) 0% 100% (8/8) 
Invasive 63% (85/134) 37% (49/134) 8% (10/123) 92% (113/123) 
ER/PR+ 59% (16/27) 41% (11/27)) 14% (1/7) 26% (22/72) 
HER2+ 61% (49/80)  38% (31/80) 43%  (3/7) 43% (31/72) 
TNBC 49% (13//27) 51% (14//27) 43% (3/7) 31%  (22/72) 
Table 3. Rictor and Raptor protein expression analysis in a human tissue 
microarray (TMA) 
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Conditional loss of RICTOR delays HER2-driven tumor formation 
  The MMTV-Neu-IRES-Cre (NIC) transgenic mouse model [128] expresses a bi-
cistronic transcript comprised of an oncogenic Neu (the rat HER2 homologue) 
expression cassette, followed by an internal ribosomal entry site (IRES) and a Cre 
recombinase expression cassette. These mice develop mammary tumors with an 
average latency of 6 months [129].  NIC mice were intercrossed with mice harboring 
floxed RICTOR alleles (RictorFL/FL) or floxed RPTOR alleles (RaptorFL/FL) to generate 
RictorFL/FLNIC mice or RaptorFL/FLNIC mice, respectively. The coupled expression of 
Neu and Cre ensures that floxed RICTOR and RPTOR alleles in all Neu-transformed 
mammary tumor cells undergo Cre-mediated recombination, eliminating Rictor and 
Raptor expression. We analyzed mammary glands of tumor-free, virgin female 
RictorFL/FLNIC  mice at 12 months of age by whole mount hematoxylin staining, 
showing that, while Rictor+/+NIC samples harbored diffuse hyperplasia within six 
months (Figure 22A, 23A), loss of Rictor in RictorFL/FLNIC mammary glands resulted 
in decreased hyperplasia through 12 months of age. Importantly, focal neoplasias 
were reduced >3-fold in RictorFL/FLNIC samples as compared Rictor+/+NIC controls 
(Figure 22B). Diffuse hyperplasia and focal neoplasias were similarly decreased in 
mature RaptorFL/FLNIC mammary glands as compared to Raptor+/+NIC siblings (Figure 
22C, 23B).  
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Figure 22. Loss of Rictor delays HER2-driven tumor formation. A-C. Mammary 
glands were assessed by whole mount hematoxylin staining. A. Representative images 
are shown. B-C. Average number of tumor foci per whole mounted gland was calculated 
for MMTV-NIC mice with floxed Rictor (B) or floxed Raptor (C) alleles.  D. Rictor+/+NIC, 
RictorFL/FLNIC , Raptor/+NIC and RaptorFL/FLNIC mice were analyzed for tumor latency. 
E. Number of tumors per genotype was calculated. F-K. Tumors harvested 28 days 
post-tumor palpation were analyzed. F. Representative images of tumor sections 
stained for H&E (top) or Ki67 (bottom). Original magnification = 400X. G. Average 
number of nuclei per 400X field is shown. Each point represents the average value from 
5 random fields/tumor.  H. Average percentage of Ki67 cells per total number of nuclei. 
Each dot represents the average value from 5 random fields/tumor.  I. IHC to detect P-
Akt (S473), original magnification = 400X.  J.  Western analysis of whole tumor lysates. 
K Intensity of phosphorylated-Akt bands normalized to total Akt was quantitated using 
Image J software. Values represent the average of each individual tumor. N = 3-4. 
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Although Rictor+/+NIC mice (N = 11) and Raptor+/+NIC mice (N = 10) formed tumors 
with 100% penetrance and an average latency of 135 and 170 days, respectively, only 
5/14 (35%) of RictorFL/FLNIC animals and 2/10 (18%) of RaptorFL/FLNIC formed tumors, 
and did so with a substantially delayed latency (Figure 22D). These findings suggest 
that both Rictor and Raptor are required individually for HER2-mediated mammary 
tumor formation. Because only two RaptorFL/FLNIC mice developed mammary tumors, 
further analysis of tumors was precluded in this model. However, we assessed the 5 
tumor-bearing RictorFL/FLNIC mice to determine the impact of Rictor loss on tumor 
progression. RictorFL/FLNIC mice developed fewer tumors per mouse as compared to 
what was seen in Rictor+/+NIC mice (Figure 22E). While tumor volume measured at 
the time of necropsy (28 days after initial tumor palpation) was similar in 
RictorFL/FLNIC and Rictor+/+NIC mice (Figure 23C), RictorFL/FLNIC tumors were distinct 
histologically from controls, harboring a lower nuclear-to cytoplasmic ratio, more 
serous fluid and more acellular debris than Rictor+/+NIC controls (Figure 23D), which 
were comprised largely of solid epithelial sheets (Figure 22F – upper panel). This 
trait was quantitated in terms of tumor cellularity, excluding large areas of acellular 
debris from analysis, revealing decreased nuclei per 400X field in 
RictorFL/FLNIC samples as compared to Rictor-expressing controls (Figure 22G). We 
used immunohistochemical (IHC) detection of Ki67 as a relative measure of tumor cell 
proliferation. For quantitation, we chose histological tumor areas where epithelial 
tumor cell density was similar in both RictorFL/FLNIC and Rictor+/+NIC samples (Figure 
22F – lower panel).  
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Figure 23. Loss of Rictor or Raptor decreases HER2-induced focal neoplasias. 
A. Image J was used to quantitate epithelial area from hematoxylin-stained whole 
mounted mammary glands isolated from the indicated mice. B.  Mammary glands 
were assessed by whole mount hematoxylin staining. C. Final tumor volume from 
indicated mice was measured upon sacrifice. D. H&E stained tumor sections from 
indicated mice. E. RNA isolated from whole tumors from the indicated mice was used 
for qRT PCR analysis of Rictor mRNA levels normalized to GAPDH. Values represent 
the average of individual tumors. Student’s T-test.   
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RictorFL/FLNIC tumors displayed a marked reduction in Ki67-positive nuclei compared to 
Rictor+/+NIC tumors, suggesting that decreased tumor progression in 
RictorFL/FLNIC samples may be due, at least in part, to decreased tumor cell proliferation 
(Figure 22H). RictorFL/FLNIC tumors harvested 28 days after initial tumor palpation 
displayed reduced phospho AKT S473- positive cells (Figure 22I) and loss of Rictor 
expression (Figure 22J) as compared to what was seen in Rictor+/+NIC tumors. AKT 
S473 phosphorylation was reduced by 80% in RictorFL/FLNIC (Figure 22K). These 
findings were confirmed by RT-qPCR analysis, demonstrating decreased RICTOR 
transcript in RictorFL/FLNIC tumors (Figure 23E). These data are consistent with the 
important role of Akt as an effector of HER2 signaling in breast tumorigenesis, and 
suggest that Rictor/mTORC2 is required for tumor cell growth and Akt phosphorylation 
in HER2-amplified tumor cells. 
Rictor loss decreases growth and Akt S473 phosphorylation in established HER2-
amplified breast cancer cells  
 mTORC2-specific inhibitors do not currently exist, however clinical trials are 
currently investigating enzymatic mTORC1/2 inhibitors. Preclinical data shows that 
mTOR inhibition is necessary for antitumor response following HER2 inhibition [130]. 
However the particular roles of mTORC1 versus mTORC2 in this regard are not entirely 
clear but warrant clarification since mTORC1 inhibition relieves negative feedback on 
oncogenic PI3K signaling, and since mTORC1/2 inhibitors are entering clinical trials in 
combination with HER2 inhibitors for HER2-amplified breast cancers.  
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Therefore, we tested if mTORC1/2 inhibition could enhance HER2-amplified breast 
cancer response to HER2 inhibition.  As expected, lapatinib treatment blocked P-
HER2 in three HER2-amplified breast cancer cell lines (SKBR3, MDA-MB-361 and 
BT474) and decreased P-S6 and P-Akt S473 (Figure 24A). Dual mTORC1/2 inhibition 
using PP242 inhibited P-S6 (a downstream effector of mTORC1) and reduced P-Akt 
S473. However, combined treatment with lapatinib and PP242 completely abolished 
P-Akt S473 and P-S6 in all three cell lines. Although PP242 and lapatinib each 
decreased growth of SKBR3, MDA-MB-361, and BT474 cells as single agents, the 
combination of lapatinib with PP242 blocked cell growth to a greater degree than 
either agent alone (Figure 24B, 25A). To distinguish the relative impact of mTORC1 
and mTORC2 in this scenario, we transduced HER2-amplified breast cancer cells with 
lentivirus encoding two distinct Rictor shRNA sequences (shRictor), Raptor shRNA 
sequences (shRaptor) and a scrambled control shRNA sequence (shScr). We 
confirmed Rictor and Raptor depletion in MDA-MB-361 (PIK3CAE545KHER2amp), 
SKBR3 (HER2amp), and BT474 (PIK3CAK111NHER2amp) cells. Cells expressing 
shRictor displayed a robust down-regulation of Rictor protein expression, and 
decreased phosphorylation of Akt S473 (Figure 24C), the mTORC2 substrate site. 
Expression of shRaptor decreased Raptor levels and phosphorylation of the mTORC1 
substrates 4EBP1 and S6 (S240) (Figure 24C). Zinc-finger nucleases (ZFNs) with 
specific homology to Rictor genomic sequences (ZFN-Rictor) were used to engineer 
homozygous RICTOR genomic deletion in MCF10A-HER2 cells, resulting in 
decreased levels of both Rictor and P-Akt S473 (Figure 25B).  
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Figure 24. Rictor loss decreases growth and Akt S473 phosphorylation in 
established HER2-amplified breast cancer cells. A. Cells were treated with PP242 
(1µM) or lapatinib (1µM) for 4 hours and analyzed by western blot. Representative 
blots are shown. B. Cells were cultured 14 days with PP242 (1 µM) or lapatinib (1µM), 
stained with crystal violet, and scanned for fluorescent area using Odyssey.  Midlines 
are the average colony area, individual points are the average values obtained for 
samples assessed in duplicate, N = 3.  C-E. Breast cancer cells expressing shRNA for 
Rictor or Raptor were assessed. C. Whole cell lysates were assessed by western 
analysis. Representative blots are shown.  D. Cells were cultured 14d, stained with 
crystal violet, and scanned for fluorescent area using Odyssey.  Midlines are the 
average colony area, individual points are the average values obtained for samples 
assessed in duplicate, N = 3.  E. Cells were embedded in Matrigel, cultured 14 days, 
and imaged. Midlines represent average number of colonies; data points represent the 
average value of duplicate samples. F-J. MDA-MB-361 shControl and shRictor 
xenografts were assessed. F. Tumors were measured and volume calculated (N = 8). 
G. Western analysis of MDA-MB-361 whole tumor lysates. H. Tumor sections were 
stained for H&E, pAkt (S473), and Ki67. Representative images are shown. Original 
magnification = 400X. I. Ki67-positive nuclei were quantitated using Image J. Data 
points represent the average value of 5 images per tumor, N = 4-5 tumors. J. Average 
number of nuclei per field is shown (midlines); each data point is average of 5 
images/tumor. 
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Figure 25. Genetic ablation of Rictor decreases growth and survival of 
HER2-positive breast cancer cells. A. Cells were cultured 14 days with PP242 
(1 uM) or lapatinib (1 uM), stained with crystal violet, and scanned for fluorescent 
area using the Odyssey system. B. Western analysis of cell lysates from 
MCF10A-HER2 cells or MCF10A-HER2-Rictor-ZFN cells. C. Cells were cultured 
14 days, stained with crystal violet, and scanned for fluorescent area using the 
Odyssey system.  D. Cells were embedded in Matrigel, cultured 14 days and 
imaged.  E. Cells were cultured 14 days, stained with crystal violet, and scanned 
for fluorescent area using the Odyssey system or embedded in Matrigel, cultured 
14 days and imaged.  Midlines represent average colony area, data points 
represent the average of duplicate samples. Data is representative of n=3 
independent experiments.  
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Rictor knockdown decreased growth of SKBR3 and MDA-MB-361 in monolayer while 
Raptor depletion decreased growth of SKBR3 cells, but not MDA-MB-361 (Figure 
24D, 25C). Similar results were found with cells embedded in three-dimensional 3D 
Matrigel, showing that knockdown of either Rictor or Raptor decreased cell growth in 
HER2-amplified breast cancer cells. Rictor ablation decreased cell growth to an equal 
or greater extent than Raptor ablation (Figure 24E, 25D). MCF10A-HER2 cells 
expressing ZFN-Rictor exhibited decreased growth in monolayer and in 3D Matrigel as 
compared to parental MCF10-HER2 cells (Figure 25E). 
  We assessed the impact of Rictor knockdown in vivo by xenografting MDA-MB-361 
cells expressing shScr and shRictor into inguinal mammary fat pads of BALB/c 
athymic (nu/nu) female mice. All tumors were palpable 7–14 days after injection, 
suggesting that Rictor depletion did not affect tumor take rate in this model. Tumor 
measurements revealed similar tumor volumes in shScr and shRictor samples at 21 d 
post-injection (Figure 24F), suggesting that early tumor growth may not be affected by 
Rictor loss.  However, by 52 d post injection, shRictor tumors were 30% smaller than 
what was seen in shScr tumors, suggesting that tumor progression in vivo requires 
Rictor. Western analysis of whole tumor lysates harvested at day 52 confirmed 
decreased Rictor and P-Akt S473 in shRictor tumors (Figure 24G). Decreased P-Akt 
S473 was similarly observed in shRictor tumors assessed by IHC (Figure 24H). Also, 
the percentage of cells expressing Ki67 was decreased in shRictor tumors (Figure 
24H, I).  
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Similar to what was seen in spontaneous RictorFL/FLNIC tumors, MDA-MB-361 
shRictor tumors displayed fewer nuclei per 400X field (Figure 24H, J). Taken 
together, these data suggest that Rictor depletion delays tumor growth and 
progression, but not tumor initiation.  
Rictor-mediated Akt activation controls survival of HER2-positive breast cancer 
cells. 
  Detection of caspase 3/7 activity demonstrated that dual mTORC1/2 inhibition 
using PP242 increased tumor cell death in HER2-amplified breast cancer cells, and 
increased caspase-mediated cell death upon treatment with lapatinib (Figure 26A). 
Because Rictor loss reduced P-Akt S473, and because Akt is a key regulator of tumor 
cell survival in HER2-amplified breast cancers [131], we tested the hypothesis that 
Rictor-mediated Akt activation is necessary for survival of HER2-driven breast cancer 
cells. Using Annexin-V labeling to detect dying cells, we found that the percentage of 
Annexin V-positive cells was increased in MDA-MB-361, SKBR3 and BT474 cells 
expressing shRictor as compared to cells expressing shScr (Figure 26B, 27A). In 
contrast, shRaptor did not increase the number of Annexin V-positive cells. Further, 
caspase 3/7 activity, which correlates with caspase-mediated cell death, was 
increased in shRictor cells as compared to shScr or shRaptor cells, suggesting that 
Rictor, but not Raptor, controls cell death of HER2-positive breast cancer cells (Figure 
26C).  MDA-MB-361 xenografts were assessed for apoptotic cells using in situ 
terminal dUTP nick end labeling (TUNEL) analysis, demonstrating a nearly 10-fold 
increase in the percentage of tumor cells that were TUNEL+ in shRictor samples as 
compared to shScr controls (Figure 26D).  
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Figure 26. Rictor/mTORC2 signaling drives Akt-mediated survival of HER2-
amplified breast cancers.  A. Cells treated with PP242 (1 µM) and lapatinib (1 µM) 
were analyzed using a luminescent caspase 3/7 assay. Midlines are the average 
luminescence, individual points are average values obtained for samples assessed in 
duplicate.  B. Cells were labeled with Annexin V-FITC for 6 hours then imaged. Midlines 
are the average percentage positive for Annexin V. Individual points are average values 
obtained for samples assessed in duplicate.  C. Cells were analyzed for caspase 3/7 
activity. Midlines are the average luminescence; individual points are average values for 
samples assessed in duplicate.  D-E. TUNEL analysis of tumor sections. 
Representative images are shown, original magnification, 600X. Midlines are the 
average percentage that was TUNEL positive; individual points are the average values 
for 5 random fields/tumor. F-G. Cells expressing AktDD or RFP were assessed. F. 
Western analysis of whole cell lysates. G. Cells labeled with Annexin V-FITC for 6h 
were imaged. Midlines are the average percentage positive for Annexin V. individual 
points are average values obtained for samples assessed in duplicate. H. Western 
analysis of cells treated with AZD5363 (500 nM) for 24 hrs. I. Cells were treated with 
AZD5363 (500 nM) for 24 hrs, labeled with Annexin V-FITC for 6 hours were imaged. 
Midlines are the average percentage positive for Annexin V. individual points are the 
average values obtained for samples assessed in duplicate. 
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Figure 27.  Rictor-mediated Akt activity is necessary and sufficient for breast 
cancer cell survival. A. Cells were labeled with Annexin V-FITC for 6 hours then 
imaged.  B. shScr, shRictor or shRaptor cells were plated and infected with either 
Ad.RFP or Ad.AktDD. At 24 hours, cells were trypsinized and cells were plated and 
allowed to sit overnight. Cells were labeled with Annexin V-FITC and imaged at 6 
hours. C. Cells were treated with AZD5363 (500 nM) for 24 hours and labeled with 
Annexin V-FITC for the final 6 hours, then imaged. . D. MCF10A-HER2 cells were 
transduced with myc-Rictor x 48 hours, plated, labeled with Annexin V-FITC for 6 
hours, then imaged. Midlines represent the average number of Annexin V-FITC 
positive cells of total cells. Value reflects average ±  SD,  n=2 plated in 
quadruplicates.  
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Similarly, the number of TUNEL+ cells was increased nearly 4-fold in spontaneous 
RictorFL/FLNIC tumors over what was seen in Rictor+/+NIC samples (Figure 26E).   
  We used adenoviral expression of an active Akt phopho-mimetic (Ad.AktDD) to 
restore Akt signaling in SKBR3 and MDA-MB-361 cells expressing shRictor, rescuing 
P-Akt S473 despite sustained Rictor depletion (Figure 26F). Restoration of Akt 
signaling in SKBR3 and MDA-MB-361 shRictor cells decreased the percentage of 
Annexin V+ cells to levels seen in shScr control cells (Figure 26G, 27B). Conversely, 
the allosteric Akt kinase inhibitor AZD5363, which decreased phosphorylation of the 
Akt substrate PRAS40 (Figure 26H), decreased survival of parental SKBR3 and 
MDA-MB-361 cells (Figure 26I, 27C). Rictor-deficient MCF10A-HER2 cells displayed 
an increased percentage of Annexin V+ cells. Re-expressing Rictor utilizing a myc-
tagged Rictor restored levels of Annexin V+ cells to that of parental cells (Figure 
27D). These results suggest that HER2-amplified breast cancer cells use Rictor-
mediated Akt signaling for cell survival.  
Rictor loss decreases migration/invasion of HER2-positive breast cancer cells. 
 Metastasis is the paramount behavior of tumor cells contributing to breast cancer 
mortality. Tumor-bearing MMTV-NIC mice develop lung metastases with nearly 100% 
penetrance, making it a useful model for studying metastasis in vivo. Using analysis of 
only tumor-bearing mice at 28 d after initial tumor palpation, we found that 90% (9/10) 
of all tumor-bearing Rictor+/+NIC mice displayed histological evidence of lung 
metastases, whereas only 60% (3/5) of all RictorFL/FLNIC mice harbored lung 
metastases (Figure 28A, B – left panel). (Tumor-free mice were not included in the 
analysis of metastatic burden.)  
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Additionally, tumor-bearing RictorFL/FLNIC mice displayed a reduced average number 
of metastases per mouse as compared to Rictor+/+NIC controls (Figure 28B – right 
panel). Low level expression of Rictor protein was detected in lung lesions from 
RictorFL/FLNIC mice, albeit in a small number of cells (Figure 29A), suggesting that 
these metastatic tumor cells may have escaped Cre-mediated Rictor loss. Metastasis 
is a multi-step process that requires cell motility and invasion (for intravasation and 
extravasation), in addition to cell survival and proliferation. We measured cellular 
invasion through Matrigel-coated transwell filters to determine if Rictor and/or Raptor 
is involved in these aspects of metastasis.  Cells expressing shScr or shRaptor were 
capable of invasion and migration through Matrigel-coated transwells (Figure 28C, 
29B). In contrast, few shRictor cells migrated through Matrigel-coated transwells. 
These results were confirmed using MCF10A-HER2 parental and Rictor-depleted cells 
(Figure 29C), again demonstrating reduced invasion and motility in the absence of 
Rictor. Because Rictor/mTORC2 is required for Rac1-mediated motility of 
untransformed MECs [62], we assessed Rac signaling in Rictor-depleted HER2-
amplified breast cancer cells using a PAK1 binding domain (PBD)-glutathione S 
transferase (GST) pull-down assay, finding decreased Rac-GTP (active Rac) in 
SKBR3 and MDA-MB-361 cells expressing shRictor as compared to what was seen in 
cells expressing shScr (Figure 28D). We used PBD-GST to probe for in situ Rac-GTP 
in tumor sections harvested from Rictor+/+NIC and RictorFL/FLNIC mice at 28 d after 
tumor palpation.  
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Figure 28. Rictor suppresses RhoGDI2 to activate Rac1 and control migration 
of HER2-positive breast cancer cells. A. H&E staining of lungs from the indicated 
mice. Representative images are shown, original magnification, 40X. B. Quantitation 
of lung metastasis in mice. Midlines in right panel represent average number of 
mets/mouse. Each data point represents an individual tumor-bearing mouse.  C. 
Transwell migration of cells 24h after plating. Midlines represent average number of 
migrating cells; points represent average value of experiments performed in 
duplicate.   D. PAK-PBD was used to pull down Rac-GTP in whole cell lysates, 
followed by immunoblot to detect Rac1. Whole cell lysates (lower panel) were 
assessed by western analysis.  E. In situ detection of GST-PBD to assess Rac-GTP 
in tumor sections. Representative images are shown. Original magnification, 400X. 
Quantitation shows the average fluorescent pixel area/group (midlines) and the 
average fluorescence in 5 random fields/sample (points). F-G. Cells expressing 
Ad.RFP or Ad.RacG12V (F) or treated with a Rac inhibitor (G) were assessed for 
transwell migration. Midlines are the average number of migrating cells; points are 
the average of samples assessed in duplicate. H-I. Whole cell lysates were 
assessed by western analysis. J. PAK-PBD was used to pull down Rac-GTP in 
whole cell lysates. Pull-downs were assessed by immunoblot to detect Rac1. Rac 
was assessed by western analysis in whole cell lysates (lower panel).  K. Transwell 
migration of cells 24h after plating. Midlines represent average number of migrating 
cells, points represent average value of experiments performed in duplicate.    
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Figure 29. Rictor-mediated Rac1 activity is necessary for breast cancer cell 
migration. A. Rictor IHC was performed on lung sections from indicated mice. B-C. 
Transwell migration of cells 24 hours after plating.  D. In situ detection of GST-PBD 
to assess Rac-GTP in tumor sections.  E. Cells were infected with Ad.RFP or 
Ad.RacG12V for 24 hrs, and analyzed for their ability to migrate through transwell 
chambers at 24 hours. F. Parental breast cancer cells were treated with a Rac1 
inhibitor and PAK-PBD was used to pull down Rac-GTP in whole cell lysates, 
followed by immunoblot to detect Rac. Whole cell lysates (lower panel) were 
assessed by western. G. Transwell migration of cells in the presence of Rac1 
inhibitor at 24 hours. Data is representative of n=3 independent experiments, 
Student’s t test. For D, n=4 tumors for Rictor+/+NIC and 3 tumors for RictorFL/FLNIC. 
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Rictor+/+NIC  tumors showed abundant GST-PBD binding, but did not demonstrate any 
binding to GST lacking the PBD motif, demonstrating the specificity of the assay 
(Figure 28E, 29D). PBD-GST binding was substantially reduced in 
RictorFL/FLNIC tumors. We rescued Rac activity in Rictor-depleted cells using 
adenoviral delivery of an active Rac1 mutant, RacG12V. We found that Ad.RacG12V 
fully rescued motility/invasion of SKBR3 and MDA-MB-361 cells expressing shRictor 
(Figure 28F, 29E). Conversely, use of a pharmacological Rac inhibitor to inhibit Rac-
GTP (Figure 29F) impaired motility/invasion of SKBR3, MDA-MB-361, and BT474 
cells (Figure 28G, 29G).   
  Although Akt can increase cell motility in many different cell types [132], re-
activation of Akt using Ad.AktDD only partially rescued cell migration in shRictor cells, 
despite full restoration of P-Akt S473 (Figure 30A). However, treatment with the Akt 
kinase inhibitor AZD4263 decreased migration/invasion of SKBR3 shScr cells, 
reducing migration to the levels seen in shRictor SKBR3 cells, but had no effect on the 
migration of MDA-MB-361 cells (Figure 30B). These data suggest that, while Akt is 
necessary for cell migration, it is not fully sufficient and that other signaling molecules 
may play a role downstream of Rictor to mediate these effects. 
Rictor activates Rac1 through suppression of RhoGDI2.   
  Additional Rictor substrates were investigated for their role in promoting 
invasion/migration of HER2-positive breast cancer cells. PKCα [133] can activate Rac 
signaling in many circumstances, and has been linked to cell motility in normal MECs 
and breast cancers.  
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Figure 30. Akt or PKCα is insufficient to rescue Rictor-mediated defects in cell 
migration and invasion. A. Cells were infected with Ad.RFP or Ad.AktDD  and 
analyzed for their ability to migrate through transwell chambers at 24 hours. B. 
Transwell migration of cells at 24 hour in the presence of AZD5363.  C. Western 
analysis of shScr or shRictor cells treated with Ad.PKCα and D. analyzed for 
transwell migration at 24 hours.  E. Cells were treated with PKCα inhibitor for 24 
hours and analyzed for transwell migration. E. Transwell migration at 24 hours in the 
presence of a PKCα inhibitor (1uM). and F. quantitation. Midlines represent average 
number of cells migrated. Individual data points represent the average of triplicate 
images for each sample. G. Cells were treated with the indicated siRNA’s for 48 
hours and analyzed for their ability to migrate through transwell chambers. Data is 
representative of n=3 independent experiments, Student’s t test. P < 0.05. 
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Adenoviral PKCα overexpression (Figure 30C) partially rescued Rictor-mediated cell 
migration defects in SKBR3 and MDA-MB-361 cells (Figure 30D). Conversely, PKCα 
inhibition significantly decreased transwell migration/invasion in parental SKBR3 cells 
but not in MDA-MB-361 (Figure 30E, F), suggesting that PKC and Rictor both 
regulate cellular migration in HER2-amplfied breast cancer cells, but using distinct and 
separable signaling pathways.   
  We examined expression of the Rac guanine exchange factor (GEF), RhoGDI2 
in HER2-amplified breast cancer cells, based on previous observations that Rictor 
causes downregulation of RhoGDI2 levels in mouse embryonic fibroblasts to modulate 
Rac1 activity [87]. While RhoGDI2 remained below the level of detection by western 
blot in SKBR3 and MDA-MB-361 cells expressing shScr, we observed accumulation of 
RhoGDI2 in cells expressing shRictor (Figure 28H). Depletion of RhoGDI2 in Rictor-
depleted cells using RhoGDI2 siRNA sequences (Figure 28I) restored Rac1-GTP 
levels to what was seen in cells expressing shScr (Figure 28J) and fully rescued cell 
migration of Rictor-depleted SKBR3 and MDA-MB-361 cells (Figure 28K, 30G). 
These data suggest that Rictor negatively regulates the Rac GEF RhoGDI2, permitting 
Rac1 activation and enhancing migration of HER2-amplified breast cancer cells. 
Loss of Rictor sensitizes parental and resistant (LR) cells to lapatinib.   
  Since Rictor supports Akt-mediated cell survival in HER2-amplified breast cancer 
cells, we tested the impact of Rictor/mTORC2 loss on therapeutically induced tumor 
cell death, using lapatinib to block HER2 kinase activity in SKBR3, MD-MB-361, and 
BT474 cells.  
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Within 0.5h, lapatinib decreased P-HER2 and P-Akt S473, as expected. However, P-
Akt S473 re-emerged after 4h lapatinib treatment, despite sustained suppression of P-
HER2 and P-S6. Resurgent P-Akt at 4h treatment correlated temporally with induction 
of Rictor protein levels (Figure 31A), and increased RICTOR mRNA (Figure 31B). 
RPTOR mRNA (Figure 32A), but not protein (Figure 31A), was increased at several 
time points but not in all cell lines and to a lesser extent than what was seen with 
RICTOR mRNA. As expected, shRictor blocked P-Akt resurgence in lapatinib-treated 
SKBR3 and MDA-MB-361 cells at 24 h (Figure 31B). SKBR3 and MDA-MB-361 cells 
expressing shRictor were treated with lapatinib, revealing that HER2 inhibition 
combined with Rictor depletion decreased P-Akt S473 to a greater extent than either 
agent alone (Figure 31C). In contrast, shRaptor had no impact on P-Akt S473. 
Although lapatinib decreased growth of SKBR3 and MDA-MB-361 cells expressing 
shScr, shRictor, and shRaptor in monolayer (Figure 31D, 32C) and in 3D Matrigel 
(Figure 31E, 32D), the combination of lapatinib plus shRictor produced the greatest 
degree of growth inhibition. Additionally, lapatinib-mediated cell death as measured by 
Annexin-V staining was highest in cells expressing shRictor as compared to shScr or 
shRaptor (Figure 31E, 32E). These data suggest that Rictor/mTORC2 targeting in 
HER2-amplified breast cancer cells improve tumor cell killing in response to lapatinib.  
  Because dual mTORC1/2 and HER2 blockade resulted in antitumor activity in 
breast tumor cells resistant to anti-HER2 therapies, we confirmed the requirement of 
mTORC1/2 in BT474 cells cultured in progressively increasing concentrations of 
lapatinib for greater than 6 months (BT474-LR) [127].  
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Figure 31. Rictor/mTORC2 loss sensitizes HER2-amplified tumor cells to 
lapatinib-mediated cell killing. A-B. Cells treated with lapatinib (1uM) were assessed 
by western blot (A) or qRT PCR (B). C. Western analysis of cell lysates with cells 
treated 4h with lapatinib (1µM).  D. Cells embedded in Matrigel were cultured 14 days ± 
lapatinib (1uM). Values shown are the average number of colonies, N =3, each 
assessed in duplicate. E. Annexin V-FITC staining of cells cultured 6h with lapatinib 
(1µM). Values shown are the average percentage of Annexin V-positive. Cells, N = 3. F. 
lapatinib-resistant BT-LR cells treated 4h ± PP242 and ± lapatinib were assessed by 
western analysis. G. BT-LR cells were embedded in matrigel and cultured 14 d ± 
PP242 and ± lapatinib. The average number of colonies is shown (midlines). H. BT-LR 
cells treated 24h ± PP242 and ± lapatinib were assessed for caspase 3/7 activity. 
Values shown are average luminescence per group (midline) and the average of 
duplicate experiments per sample (points).  I. Immunoprecipitation of mTOR from whole 
cell lysates harvested from parental and lapatinib-resistant BT-474 cells, followed by 
immunoblot for Rictor or Raptor. J. Whole cell lysates were assessed by western 
analysis. K-M Parental or shRic BT LR cells were plated for growth in (K) 2D or (L) 3D 
Matrigel or (M) analysis of Annexin V –FITC staining. Values shown are the average 
value for each group. Points represent the average value from samples assessed in 
duplicate.  
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Lapatinib resistant BT474-LR cells treated with lapatinib in the presence or absence of 
PP242 revealed that, while P-AktS473 was unaffected by lapatinib treatment, PP242 
abolished P-Akt S473 and reduced P-S6, consistent with mTORC1 and mTORC2 
inhibition (Figure 31F).  Further, PP242, but not lapatinib, decreased growth of 
BT474-LR cells cultured in monolayer (Figure 31G, Figure 32F), through induction of 
cell death as measured by detection of caspase 3/7 activity (Figure 31H). 
Interestingly, maximal growth inhibition was seen using the combination of lapatinib 
and PP242.  
  We examined mTORC2 complex assembly in parental and lapatinib-resistant 
BT474 cells using co-immunoprecipitation (co-IP) for mTOR with Rictor. Rictor co-
precipitated with mTOR in both parental and lapatinib resistant cells (Figure 31I), 
confirming mTORC2 complex assembly. Interestingly, Raptor co-precipitated with 
mTOR to a lesser extent in lapatinib-resistant cells as compared to what was seen in 
parental BT474 cells.  We next assessed the effects of Rictor/mTORC2 targeting on 
growth of lapatinib-resistant cells (Figure 31J). BT LR cells expressing shScr cultured 
in the presence of lapatinib expressed P-Akt S473, consistent with what has been 
described previously for BT474-LR cells. Rictor knock-down using shRictor resulted in 
blocked Akt S473 phosphorylation, even in lapatinib resistant cells (Figure 31J). While 
lapatinib reduced growth of parental BT474 cells in monolayer (Figure 31K), lapatinib 
did not affect growth of BT474-LR cells, confirming lapatinib resistance. However, 
shRictor decreased growth of BT474-LR cells cultured either with or without lapatinib 
(Figure 33A).  
121 
 
 
  
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Loss of Rictor/mTORC2 sensitizes parental and resistant cells to 
lapatinib in vitro.  A. Parental cells were treated with lapatinib for the indicated time and 
analyzed by qRT PCR to assess human Raptor mRNA levels. Values were normalized 
to GAPDH levels. B. Rictor knockdown cells were treated with lapatinib and analyzed by 
western blot. C-E. shScr, shRic or shRap cells were treated with DMSO or lapatinib and 
analyzed for  C. 2D growth, D. 3D growth in Matrigel E. Annexin V-FITC staining. 
Representative images are shown. Quantitation was performed using ImageJ software. 
F. BT LR cells were analyzed for 2D growth in the presence of the indicated drugs. 
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Similar results were observed using cells cultured in 3D Matrigel, demonstrating that 
BT474-LR cells were insensitive to lapatinib-mediated growth inhibition, but formed 
fewer colonies upon depletion of Rictor (Figure 31L, 33B). As expected, BT474-LR 
expressing shScr did not display increased cell death in response to lapatinib (Figure 
31M, 33C). However, shRictor-expressing BT474-LR cells exhibited increased cell 
death as compared to BT474-LR cells expressing shScr and the combination of 
lapatinib with shRictor loss produced >3-fold increase in BT474-LR cell death. Thus 
far, our data suggests that parental and LR cells use Rictor/mTORC2 for survival and 
growth. As Rac1 is a major downstream signaling node of mTORC2, we aimed to 
determine if Rac1 inhibition could decrease growth and survival of LR cells, in a 
similar way to mTORC1/2 inhibition. While BT474 LR cells did not respond to lapatinib 
with decreased growth or increased cell death, treatment with a small molecular 
inhibitor of Rac1 (Figure 33D) almost completely abolished growth in monolayer 
(Figure 33E), likely due to cell death as measured by a significant induction of 
caspase-mediated cell death (Figure 33F).  
  Taken together, our data uncovers a novel role for Rictor/mTORC2 in directly 
activating Akt and Rac to support the growth, survival and migration of HER2-
amplified breast cancer cells. Targeting Rictor/mTORC2 or its downstream effector, 
Rac1, in combination with lapatinib may be clinically beneficial to patients with HER2-
amplified tumors, including those with acquired resistance to the EGFR/HER2 
inhibitor, lapatinib.  
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Figure 33. Loss of Rictor/mTORC2 or Rac1 sensitizes resistant cells to the cell 
killing effects of lapatinib in vitro A. Lapatinib-resistant (LR) cells with stable 
lentiviral knockdown of Rictor were cultured 14 days, stained with crystal violet, and 
scanned for fluorescent area using the Odyessey system. B.  Cells were embedded in 
Matrigel, cultured 14 days and imaged.  C.  Cells were labeled with Annexin V-FITC for 
6 hours, then imaged.  D-F. BT474 LR cells were treated with lapatinib, Rac inhibitor or 
lapatinib (1uM) + Rac inhibitor. D.  Cell lysates were analyzed by GST-PBD pulldown to 
assess Rac-GTP levels (active Rac). E. Cells were cultured in the presence of the 
indicated inhibitors for 14 days, stained with crystal violet, and scanned for fluorescent 
area using the Odyssey system. F. Cleaved caspase 3/7 activity in cells treated with 
indicated drugs. 
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Discussion  
 The studies presented here uncover the key roles played by mTORC2/Rictor in 
HER2-amplified breast cancer initiation, maintenance, progression, and metastasis. 
Abundant pre-clinical studies demonstrate that Akt/mTOR is a critical signaling node 
requiring inhibition in order to achieve a full therapeutic response in HER2-amplified 
breast cancers. However, most clinical and preclinical studies have focused primarily 
on mTORC1. This may be due to the fact that mTORC1 is seen as a direct 
downstream effector of the HER2/PI3K pathway, or perhaps due to the availability of 
pharmacological mTORC1-specific inhibitors, but not mTORC2-specific inhibitors. 
Increasing evidence suggests that mTORC1 inhibition promotes resurgent PI3K 
signaling due to loss of mTORC1-mediated negative feedback on the PI3K pathway, a 
potentially troublesome scenario when targeting tumors that thrive on HER2-activated 
PI3K signaling. The more recent development of mTOR kinase inhibitors, which will 
target both mTORC1 and mTORC2, has generated intense interest. Yet little is known 
about mTORC2-specific signaling in HER2-amplified breast cancers.  Our analysis, 
using novel transgenic mouse models and genetic inhibition of mTORC1 versus 
mTORC2, reveals a vital role for Rictor/mTORC2 in the growth, survival and migration 
of HER2-amplified breast tumors and in their response to lapatinib, including those 
with acquired resistance to lapatinib. 
 Interestingly, we found increased Rictor expression in HER2-amplified human 
breast cancer cell lines and in human breast tumors. Further, Rictor intensity was 
highest in high-grade breast tumors, while Raptor intensity was similar across non-
invasive or invasive breast cancer and adjacent normal tissue.  
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Interrogation of the TCGA database revealed that RICTOR or MAPKAP1, but not 
RPTOR, gains correlate with decreased patient survival. At least one additional study 
supports our findings that Rictor is overexpressed in human breast tumors. Zhang et 
al reported increased immunohistochemical detection of Rictor in primary breast 
tumors, correlating Rictor overexpression with lymph node metastasis [55]. 
Overexpression of another critical mTORC2-specific component, Sin1 (encoded by 
MAPKAP1), has been reported in aggressive papillary thyroid carcinoma and is 
associated with aberrantly elevated Akt phosphorylation [134]. These observations 
support a potential role for mTORC2 components in aggressive tumors and highlights 
Rictor/mTORC2 as a potential therapeutic target. 
  Conditional loss of either RICTOR or RPTOR in a transgenic mouse model of 
HER2-driven breast cancer decreased and delayed tumor formation, demonstrating 
that Rictor is necessary for the genesis of these tumors, and confirming a previously 
defined role for mTORC1 in the genesis of HER2/Neu-dependent mammary tumors 
[135, 136]. We found that Rictor depletion decreased Akt S473 phosphorylation (but 
not Akt T308 phosphorylation), decreased tumor cell growth and survival, and 
significantly diminished tumor cell metastasis.  This strong in vivo data is supported by 
cell culture experiments showing that genetic RICTOR, but not RPTOR, loss 
decreased Akt activation (phosho-S473), cell survival and invasion/motility of multiple 
HER2-amplified breast cancer cell lines, including lines with activating PIK3CA 
mutations.  
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  Abundant data highlight the key role of Akt signaling as a downstream effector of 
HER2 signaling in HER2-amplified breast cancers. Akt is phosphorylated downstream 
of two main pathways, the PI3K pathway (via PDK1 at T308) and the mTORC2 
pathway (at S473) [137].  However, other kinases have been reported to 
phosphorylate Akt S473, including Inhibitor of B-Kinase (IKK)-, DNA protein kinase 
(DNA-PK), and Integrin-Linked Kinase (ILK) [17]. Because Rictor loss decreases Akt 
S473 phosphorylation in these cells, and because expression of an active Akt mutant 
rescued cell survival in Rictor-depleted cells, it is possible that HER2-amplified breast 
cancers may be particularly reliant on mTORC2/Rictor for Akt S473 phosphorylation, 
revealing a potential vulnerability to mTORC2 inhibition in HER2-amplified cancers.  
  In our studies, restoration of Akt1 was sufficient to fully restore cell survival 
downstream of Rictor; however it could only partially rescue the invasion defects 
exerted by the loss of Rictor. Several lines of evidence suggest that cancer cells 
exploit Rictor-dependent signaling pathways to facilitate invasion and metastasis. For 
example, siRNA-mediated Rictor depletion decreased migration of MCF7 and MDA-
MB-231 cells [55, 68]. In gliomas, Rictor overexpression promoted mTORC2 activity 
and tumor cell growth and motility [64].  Additionally, Rictor may interact with PKC 
isoforms to regulate breast cancer metastasis [55], although we found that PKC 
inhibition only partially inhibited migration in HER2-amplified breast cancer cells, while 
PKC restoration only partially rescued invasion/migration of Rictor-depleted HER2-
amplified cells. Our Rictor-deficient HER2-amplified breast cancer cell lines and 
tumors exhibited significantly decreased Rac1 activity.  
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  Recent studies in mouse embryonic fibroblasts show that Rictor suppresses 
RhoGDI2 expression, a negative regulator of Rac1 and a metastasis suppressor gene, 
thus allowing increased Rac1-mediated cell motility [87]. In support of these data, we 
show that Rictor downregulation in breast cancer cells results in accumulation of 
RhoGDI2 protein. Genetic ablation of RhoGDI2 in Rictor knockdown cells rescued 
Rac1 signaling and fully restored their migratory and invasive abilities, suggesting that 
Rictor negatively regulates RhoGDI2, allowing for full activation of Rac and increased 
cell motility. Although these data are the first (to our knowledge) linking Rictor to Rac1-
mediated invasion and metastasis of breast cancer cells, Rictor-to-Rac1 signaling has 
been previously identified for cancers originating from other tissues [114-116], and 
previous studies have shown that HER2-amplified breast cancer cells use p120 
Catenin-to-Rac1 signaling to promote breast cancer metastasis [138] 
  Taken together, our novel data highlight a signaling axis where Rictor relieves 
RhoGDI2-mediated blockade of Rac1 signaling, thus promoting dissemination of 
HER2-amplified breast cancer cells.  Interestingly, this is distinct from untransformed 
mammary epithelial cells (MECs) which rely on an Akt-independent Rictor-PKCa-Rac1 
signaling axis to control mammary morphogenesis, MEC survival and invasion [62] 
suggesting that untransformed mammary epithelial cells utilize pathways distinct from 
HER2-driven tumor cells, which may possess increased reliance on Akt for cell 
survival and may downregulate RhoGDI2 to enhance Rac1 signaling and migratory 
ability.  
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Efficient metastatic progression relies on a coordinated series of steps involving cell 
motility and invasion (for intravasation and extravasation), in addition to cell survival 
and proliferation. While we show that Rictor loss decreases metastatic ability of HER2-
driven breast tumors and that Rictor/mTORC2 directly controls cell migration, we have 
not ruled out the potential impact Rictor loss may have on survival of disseminated 
tumor cells and how this may affect seeding/establishment of overt lung metastases in 
our model.  
 The PI3-kinase (PI3K)/mTOR pathway is aberrantly activated up to 60% of clinical 
breast cancers, facilitating tumor cell growth, survival, metabolism, and invasion [105, 
106]. Although mTORC1 signaling is abundantly upregulated in HER2-amplified 
cancers, inhibitors of mTORC1 show limited clinical efficacy as single agents. In 
agreement with these observations, we found that Raptor/mTORC1 ablation 
effectively inhibited cell growth, but not cell survival or cell invasion in HER2-amplified 
breast cancer cells. In contrast, Rictor/mTORC2 ablation decreased cell growth, 
survival, and invasion suggesting that mTORC2 targeting may be a more efficacious 
approach.  Our findings are supported by a recent report in which heregulin/HER2-
driven breast cancer cell lines required mTORC2 for their cell survival [139]. Although 
mTORC2-specific inhibitors are not yet available, dual mTORC1/2 inhibitors are being 
met with some success, and are being investigated in combination with currently 
available inhibitors of HER2 and PI3K.  
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We show here that treatment of HER2-positive breast cancer cells with the 
mTORC1/2 inhibitor, PP242, sensitized parental and lapatinib-resistant cells to the 
growth inhibitory effects of lapatinib, findings that are consistent with several recent 
studies combining anti-HER2 agents or anti-PI3K agents with dual mTORC1/2 
inhibitors [67, 108-110] [140]. Taken together, these studies underscore the clinical 
relevance of mTORC2 in breast cancer.  
  In summary, we have used clinical breast cancer datasets along with 
spontaneous and cell culture-based models of breast cancer to reveal previously 
unreported roles for Rictor/mTORC2 in the genesis, maintenance, progression, and 
metastasis of HER2-driven breast cancers. We have shown that targeted inhibition of 
Rictor/mTORC2 is effective at each stage in the natural history of HER2-amplified 
tumors. These data support continued translation investigation of dual mTORC1/2 
inhibitors to improve the outcome for patients with HER2-amplified breast cancers, 
and warrant future efforts to develop mTORC2-specific inhibitors. 
 
 
 
 
 
 
 
 
 
131 
 
Chapter IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 mTOR is a well-studied kinase that plays necessary roles in both physiology and 
in disease. It has become increasingly apparent that mTOR influences most cellular 
functions including cell growth, proliferation, metabolism, survival and migration. While 
essential roles for mTOR have been described in brain, adipose tissue, muscle, and 
liver under physiological conditions the differential roles of mTORC1 and mTORC2 have 
not been explored in regards to post-natal mammary gland development. Bridging this 
knowledge gap would not only highlight the important and distinct roles of mTORC2 in 
the normal epithelium, but also would likely provide information regarding the 
mammary-specific signaling pathways that cancer cells could hijack to drive breast 
tumor formation, progression, and therapeutic resistance.  To date, breast cancer 
research and to some extent, mammary gland development research, has focused 
particular attention on mTORC1, perhaps due to its location within its signaling pathway 
downstream of PI3K, and in part due to the commercial and clinical development of 
mTORC1 inhibitors. However, a growing body of data highlighting a key role of for 
mTORC2 in various cancer types exists, including PI3K-driven prostate and 
glioblastoma. When the research project described herein was initiated, the role of 
mTORC2 in breast cancer was understudied. 
132 
 
The work presented here was the first, to our knowledge, to dissect the differential roles 
of mTORC1 and mTORC2 in post-natal mammary morphogenesis, to elucidate how 
these signaling complexes are used by cancer cells to mediate survival and migration, 
and to identify the novel and unique role of mTORC2 in breast development and cancer.  
Rictor/mTORC2 is required for normal mammary gland development 
 These studies are the first to demonstrate the requirement for Rictor/mTORC2 in 
untransformed MECs for their survival, migration and morphogenesis. Interestingly, 
these processes relied fully on a PKCα-Rac1 signaling axis. Surprisingly, we found that 
Akt, a main downstream mTORC2 effector, was necessary but not sufficient to rescue 
defects caused by Rictor ablation. In contrast, Raptor/mTORC1 ablation only caused 
minor and transient defects in proliferation of MECs at 6 weeks.  
At the onset of puberty, MECs in glands of Rictor wildtype mice exhibited rapid 
proliferation and developed complex, branched structures that fully invaded into the 
mammary fat pad by 10 weeks of age. In contast, RictorMGKO glands exhibited reduced 
fat pad filling at both 6 and 10 week time points, manifested as decreased ductal length 
and diminished side branching in whole mounted mammary glands. These defects were 
due, at least in part, to reduced proliferation, as measured by Ki67 staining of luminal 
MECs, which was observed at 6 weeks of age, but resolved by 10 weeks of age. 
Additionally, cell death, as measured by TUNEL staining, was significantly increased at 
both 6 and 10 weeks of age in Rictor-deficient mammary glands. In contrast, Raptor-
deficient mammary glands displayed only transient decreases in proliferation and ductal 
outgrowth at 6 weeks, which resolved by 10 weeks, and no alteration in cell death.   
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Thus, loss of Rictor/mTORC2 impairs survival, proliferation and branching 
morphogenesis in vivo, a phenotype distinct from that produced by loss of 
Raptor/mTORC1. 
Subsequent studies utilizing ex vivo manipulation of PMECs revealed molecular 
pathways downstream of Rictor contributing to these processes. Loss of Rictor 
significantly reduced P-Akt S473 levels cell survival, cell invasion and branching 
morphogenesis in 3D Matrigel. In contrast Raptor loss decreased phosphorylation of 
S6, an mTORC1 target but did not affect Akt phosphorylation, cell survival, cell invasion, 
or branching morphogenesis. These results reveal that mTOR operates primarily within 
mTORC2 to drive cell survival and motility within the untransformed mammary 
epithelium. Surprisingly, Akt restoration in Rictor-deficient MECs only modestly 
enhanced branching morphogenesis, while Akt inhibition in wild-type MECs decreased 
mammary branching and colony size. These results suggest that Akt is necessary but 
not sufficient to drive branching morphogenesis in the absence of Rictor. Further, Akt 
restoration in Rictor-null MECs was not sufficient to rescue MEC invasion or survival, 
suggesting other factors downstream of Rictor/mTORC2 regulate these processes in 
normal mammary gland development. To this end, restoration of PKCα signaling to 
Rac1, or Rac1 activation independently of upstream signals, fully rescued all 
phenotypes resulting from Rictor loss in cell culture and in transplanted Rictor-deficient 
MECs in vivo. Therefore, Rictor-dependent mTORC2 is essential for PKCα-Rac1 
signaling to drive mammary morphogenesis.  
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Rictor/mTORC2 drives progression and therapeutic resistance of HER2-amplified 
breast cancers 
 As these results show that Rictor/mTORC2 is necessary in untransformed MECs 
and because molecular pathways that regulate normal mammary gland development 
are often commandeered by cancer cells to support their growth and survival, we tested 
the requirement of Rictor/mTORC2 in tumor cells. We used clinical breast cancer 
datasets, spontaneous tumor mouse models and cell culture-based models of human 
breast cancer to reveal previously unreported roles for Rictor/mTORC2 in the 
maintenance, progression, and metastasis of HER2-driven breast cancers. We 
demonstrated that Rictor/mTORC2 is necessary for migration of the HER2-amplified 
breast cancer cell lines, SKBR3, MDA-MB-361 and BT474, which rely on Rictor-
mediated Rac1 signaling for enhanced migration. While Rictor knockdown decreased 
Rac activity, a constitutively active Rac mutant fully rescued migration defects in Rictor-
deficient breast tumor cells. Importantly, spontaneous HER2-dependent mammary 
tumors required Rictor for Rac activity and metastasis to lungs, in part due to 
accumulation of the Rac1 inhibitor, RhoGDI2 upon Rictor loss. These data suggest that 
inhibition of mTORC2-to-Rac signaling may block tumor cell metastasis.  
 As expected based on the role of mTORC2 in Akt phosphorylation, Rictor loss 
from HER2-amplified breast tumor cells, and from spontaneous mouse mammary tumor 
models of HER2-amplified breast cancer, resulted in decreased Akt phosphorylation 
and decreased cell survival.  
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Because Rictor supported Akt-mediated cell survival in HER2-amplified breast cancer 
cells, we tested the impact of Rictor/mTORC2 loss on therapeutically induced tumor cell 
death, using lapatinib to block HER2 kinase activity in HER2-amplified breast cancer 
cell lines.  Lapatinib treatment induced Rictor protein expression at 8-24 hours post-
treatment and this corresponded with resurgent Akt activation. Blocking Rictor in 
combination with lapatinib resulted in greater cell death and greater inhibition of P-Akt 
than either condition alone. Interestingly, Rictor loss combined with lapatinib treatment 
resulted in greater inhibition of cell growth than loss of Raptor and lapatinib.  
Because lapatinib treatment induced Rictor protein expression which correlated 
with reactivation of P-Akt, we tested the requirement for Rictor in HER2-positive breast 
cancer cells that had been cultured in increasing concentrations of lapatinib to generate 
lapatinib-resistant (LR) cells. Cells with acquired resistance to the HER2 inhibitor 
lapatinib retained P-Akt S473 following lapatinib treatment, but lost P-Akt S473 upon 
Rictor ablation. Additionally, while BT LR cells did not respond to lapatinib with 
increased cell death, as expected, loss of Rictor in combination with lapatinib treatment 
resulted in significantly increased cell death compared to lapatinib or DMSO control. 
 Because our studies demonstrate that Rac1 is a major downstream signaling 
effector of mTORC2, we sought to determine if Rac1 inhibition in combination with 
lapatinib would recapitulate the effects we saw with Rictor loss in combination with 
lapatinib. Indeed, Rac1 inhibition sensitized LR cells to growth inhibitory and cell-killing 
effects of lapatinib.  
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These results suggest that mTORC2-Akt signaling remains an Achilles heel in lapatinib-
resistant HER2-amplified breast cancers, an observation that might be exploited 
currently using dual mTORC1/2 inhibitors, or in the future pending the development of 
mTORC2-specific inhibitors.  
 Taken together, our data uncovers a novel role for Rictor/mTORC2 in directly 
activating Akt and Rac to support the growth, survival and migration of HER2-amplified 
breast cancer cells. Targeting Rictor/mTORC2 or its downstream effector, Rac1, in 
combination with lapatinib may be clinically beneficial to patients with HER2-amplified 
tumors, including those with acquired resistance to the EGFR/HER2 inhibitor, lapatinib.  
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Future directions 
The role of Rictor/mTORC2 in the alveolar epithelium during pregnancy/lactation 
During pregnancy, luminal MECs rapidly proliferate and differentiate to generate 
milk-producing alveolar cells [2].  We have demonstrated that loss of Rictor results in 
decreased ductal lengthening during puberty, decreased cell motility and cell survival ex 
vivo, and decreased Akt phosphorylation at S473 in vivo and ex vivo. Based on this 
data, it is plausible that loss of Rictor in the alveolar epithelium will also display 
decreased phosphorylation of Akt at S473, due to decreased mTORC2 activity and that 
this will correlate with decreased survival in alveolar MECs. Cell survival in the alveolar 
epithelium is required to sustain lactation once pups begin nursing. Accordingly, loss of 
Akt1 similarly impairs survival of milk-producing alveolar cells in lactating mammary 
glands [40]. It is therefore possible that loss of Rictor will impair cell survival in the 
alveolar epithelium, resulting in a phenotype similar to that induced by loss of Akt1.  
Additionally, preliminary data from our lab suggests that Rictor loss in ductal MECs 
impairs localization of ZO-1, a tight junction protein necessary for proper cell 
polarization of epithelial cells. As proper polarization is necessary for alveolar cell 
structure and functionality [141] it will be important to determine the effects of Rictor 
ablation on MEC polarization, growth, differentiation, and milk production in alveolar 
mammary epithelium during pregnancy and lactation in vivo.  
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Breast cancer subtype-specific roles for mTORC2 
Data outlined in this dissertation reveals a necessary and previously unreported 
role for Rictor/mTORC2 in the growth, survival and migration of HER2-amplified breast 
cancer cells. Our results are supported by additional in vitro studies showing that 
Rictor/mTORC2 is necessary for heregulin-mediated growth of HER2-positive breast 
cancer cells [139]. While we, and others, have explored the role of Rictor/mTORC2 in 
HER2-driven breast tumors, it is probable that Rictor/mTORC2 is necessary for similar 
processes in additional subtypes of breast cancer. Indeed, we found that Rictor mRNA 
and protein levels were elevated in several human, ER-positive, luminal breast cancer 
cell lines, including ZR75-1 and HCC1428 cells. Intriguingly, TCGA-curated data shows 
a significant correlation between RICTOR copy number gain and decreased survival in 
luminal breast cancers (data not shown, TCGA, P< 0.01). Additional, unpublished data 
from our lab has shown that loss of Rictor decreases P-Akt S473, decreases growth, 
survival and migration in MCF7 cells, similar to our findings in HER2-amplified breast 
cancer cells.  
 This is supported by several published studies demonstrating that Rictor 
knockdown suppressed anchorage-independent growth of MCF7 breast tumor cells 
[111] and that Rictor controls survival and migration of MCF7 (ER-positive) [142] and 
MDA-MB-231 (basal-like) breast cancer cells [69]. It is also clear that mTORC2 plays a 
necessary role in PI3K-driven prostate [63] and glioblastomas [64]. PIK3CA mutations 
are most abundant in luminal/ER+ breast cancers, suggesting this also may be true for 
PI3K-driven breast tumors.  
139 
 
As preclinical data using everolimus, an mTORC1 inhibitor, also confirms a role for 
mTORC1 in luminal breast cancers, additional research is necessary to understand the 
specific contribution of mTORC1 versus mTORC2 in the luminal subtype of breast 
cancer and in response to antiestrogens.   
Rictor/mTORC2 in breast tumor cell metabolism 
 Increasing evidence from multiple cell types has demonstrated a necessary role 
for Rictor/mTORC2 in control of cellular metabolism. For example, liver-specific 
knockout of Rictor, which impaired Akt and PKCa activation, resulted in decreased 
glycolysis and lipogenesis, both key processes that are necessary for rapid proliferation 
to support uncontrolled tumor growth [30]. In glioblastoma cells, mTORC2 plays a 
central role in cancer metabolic reprogramming, controlling glycolytic metabolism 
through direct, inactivating phosphorylation of class IIa HDACs, leading to acetylation of 
FOXO1 and FOXO3, which releases suppression of c-myc by miRNA’s [143].  In 
glioblastoma patients, activated mTORC2 was highly correlated with shorter survival. 
Overall, these studies defined a specific, Akt-independent role for mTORC2 in 
regulating glycolytic metabolism in glioblastoma. Therefore, it is interesting to speculate 
that a direct link between mTORC2 and anabolic processes in breast cancer cells could 
also exist. While the role of mTORC2 in glycolytic metabolism of breast cancer cells 
hasn’t been directly tested, a recent study demonstrated that mTORC2 controls 
lipogenesis in breast cancer cells through direct regulation of SREBP1 [144].  
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Based on these data, it would be important to assess if loss of Rictor in breast cancer 
cells impairs the function of lipogenic enzymes (like fatty acid synthase, FASN), 
transcription factors that regulate lipogenesis downstream of Akt (SREBP), and other 
controllers of breast cancer cell metabolism.  
Targeting Rictor/mTORC2 for treatment of breast cancer 
 HER2-driven breast cancers are treated with HER2-targeted therapies but nearly 
100% of metastatic HER2-positive breast cancers acquire resistance to HER2 
inhibitors, underscoring a desperate need for new therapeutic targets in HER2- 
amplified breast cancers. Preclinical studies demonstrated that everolimus, an 
mTORC1 inhibitor that can inhibit mTORC2 through indirect mechanisms in some cell 
types, sensitized HER2-amplified tumors to the HER2 monoclonal antibody, Herceptin. 
In these studies, everolimus inhibited both mTORC1 and mTORC2. And although ATP 
competitive mTORC1/2 inhibitors effectively prevent mTORC2 activity, the negative 
consequences of mTORC1 inhibition [compensatory activation of PI3K signaling, 
immunosuppression] may limit their therapeutic potential.  For example, a recent study 
showed that inhibition of mTOR kinase caused activation of receptor tyrosine kinase 
signaling which re-induced PI3K signaling, Akt phosphorylation at T308 and, despite 
persistent inhibition of mTORC2 activity and AKT S473 phosphorylation [145]. This 
PI3K pathway reactivation could severely limit clinical utility of these inhibitors and prove 
detrimental to patients treated with these drugs. Thus, while the role of mTOR in HER2-
positive breast cancer is evident, a knowledge gap remains regarding the specific role 
and therapeutic potential of mTORC2 inhibitors in HER2-amplified, PI3K-dependent 
breast cancers.  
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 mTORC2-specific inhibitors do not currently exist, but one may postulate how these 
could be designed. For example, small molecule inhibitors could be designed that target 
the interaction between Sin1 and mTOR, which is necessary for proper assembly and 
activation of mTORC2. Additionally, XPLN, an endogenous inhibitor of mTORC2 that 
preferentially interacts with mTORC2, but not mTORC1, has recently been described 
[146]. As an N-terminal, 125-amino-acid fragment of XPLN was found to be both 
necessary and sufficient for the inhibition of mTORC2 and downstream signaling, it is 
possible that fragment could be exploited for inactivation of mTORC2 in tumor cells.   
 In conclusion, data outlined in this dissertation shows a necessary role for 
Rictor/mTORC2 in growth, survival and migration of HER2-driven tumor cells. 
Importantly, we also demonstrate that loss of Rictor/mTORC2 signaling sensitizes 
parental and resistant cells to lapatinib and that loss of Rictor/mTORC2 signaling 
produces a greater anti-proliferation effect when combined with lapatinib than loss of 
Raptor/mTORC2 combined with lapatinib. This suggests that targeting Rictor/mTORC2 
in combination with lapatinib, while sparing direct inhibition of mTORC1, may be a 
favorable approach in breast cancer and is clear evidence that mTORC2-specific 
inhibitors need to be further explored.  
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